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Abstract: Alzheimer's disease [AD] is the most common cause of dementia in North America. Despite 30+ years of in-
tense investigation, the field lacks consensus regarding the etiology and pathogenesis of sporadic AD, and therefore we 
still do not know the best strategies for treating and preventing this debilitating and costly disease. However, growing evi-
dence supports the concept that AD is fundamentally a metabolic disease with substantial and progressive derangements 
in brain glucose utilization and responsiveness to insulin and insulin-like growth factor [IGF] stimulation. Moreover, AD 
is now recognized to be heterogeneous in nature, and not solely the end-product of aberrantly processed, misfolded, and 
aggregated oligomeric amyloid-beta peptides and hyperphosphorylated tau. Other factors, including impairments in en-
ergy metabolism, increased oxidative stress, inflammation, insulin and IGF resistance, and insulin/IGF deficiency in the 
brain should be incorporated into all equations used to develop diagnostic and therapeutic approaches to AD. Herein, the 
contributions of impaired insulin and IGF signaling to AD-associated neuronal loss, synaptic disconnection, tau hyper-
phosphorylation, amyloid-beta accumulation, and impaired energy metabolism are reviewed. In addition, we discuss cur-
rent therapeutic strategies and suggest additional approaches based on the hypothesis that AD is principally a metabolic 
disease similar to diabetes mellitus. Ultimately, our ability to effectively detect, monitor, treat, and prevent AD will re-
quire more efficient, accurate and integrative diagnostic tools that utilize clinical, neuroimaging, biochemical, and mo-
lecular biomarker data. Finally, it is imperative that future therapeutic strategies for AD abandon the concept of uni-modal 
therapy in favor of multi-modal treatments that target distinct impairments at different levels within the brain insulin/IGF 
signaling cascades. 
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ALZHEIMER'S DISEASE AND BRAIN GLUCOSE 
METABOLISM 
  Alzheimer's disease [AD] is the most common cause of 
dementia in North America, and over the past several dec-
ades, the prevalence rates of sporadic AD have become epi-
demic [1]. Although the clinical diagnosis of AD is based on 
criteria set by the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer's 
Disease and Related Disorders Association (NINCDS/ 
ADRDA) and DSM-IV criteria [2], embracement of addi-
tional tools such as neuroimaging and standardized bio-
marker panels could facilitate early detection of disease [3]. 
Characteristic neuropathological hallmarks of AD include: 
neuronal loss, abundant accumulations of abnormal, hyper-
phosphorylated cytoskeletal proteins in neuronal perikarya 
and dystrophic fibers, and increased expression and abnor-
mal processing of amyloid-beta precursor protein (APP), 
leading to APP-A peptide deposition in neurons, plaques, 
and vessels. For nearly three decades, the dominant trends 
have been to interpret selected AD-associated abnormalities, 
namely the hyper-phosphorylation of tau and deposition of  
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APP-A as causal rather than consequential to the neu-
rodegeneration cascade. This approach posed significant 
limitations on the scope of investigation and the goals with 
respect to designing new treatments; ergo, success has been 
either modest or disappointing. On the other hand, due to 
collected contributions of a number of researchers, the field 
has recently become more receptive to alternative concepts, 
opening the doors to exciting new avenues of investigation 
and therapeutic strategies. 
  Growing evidence supports the concept that AD funda-
mentally represents a metabolic disease in which brain glu-
cose utilization and energy production are impaired [4-8]. 
Metabolic abnormalities have been linked to brain insulin 
and insulin-like growth factor (IGF) resistance with disrup-
tion of signaling pathways that regulate neuronal survival, 
energy production, gene expression, and plasticity [4]. On a 
cellular basis, inhibition of insulin/IGF signaling contributes 
to AD-type neurodegeneration by increasing: 1) the activity 
of kinases that aberrantly phosphorylate tau; 2) expression of 
APP and accumulation of APP-A; 3) levels of oxidative 
and endoplasmic reticulum (ER) stress; 4) the generation of 
reactive oxygen and reactive nitrogen species that damage 
proteins, RNA, DNA, and lipids; 5) mitochondrial dysfunc-
tion; and 6) activation of pro-inflammatory and pro-death 
cascades. On a functional basis, insulin/IGF resistance 
causes down-regulation of target genes that are needed for 36    Current Alzheimer Research, 2012, Vol. 9, No. 1  Suzanne M. de la Monte 
cholinergic homeostasis, and it compromises systems that 
mediate neuronal plasticity, memory, and cognition.  
  The gold standard for definitively diagnosing AD is to 
perform a postmortem examination of the brain, with the 
objective of demonstrating beyond-normal aging associated 
densities of neurofibrillary tangles, neuritic plaques, and 
APP-A deposits in corticolimbic structures, bearing in 
mind that neurodegeneration frequently involves multiple 
other cortical regions as well. The common thread among 
these characteristic lesions is that they harbor insoluble ag-
gregates of abnormally phosphorylated and ubiquitinated tau, 
and neurotoxic APP-A in the form of oligomers, fibrillar 
aggregates, or extracellular plaques. Secreted APP-A oli-
gomers have been demonstrated to be neurotoxic and to in-
hibit hippocampal long-term potentiation, i.e. synaptic plas-
ticity [9].  
  Ultimately, to improve our capacity for diagnosis and 
treatment, we should be able to connect the development and 
progression of neuropathological lesions with the molecular, 
biochemical, physiological, neuro-imaging, and clinical ab-
normalities that correlate with AD. Therefore, gaining a bet-
ter understanding of the pathophysiology of these lesions 
could improve our current diagnostic and treatment ap-
proaches to AD. One way to begin the process in earnest is 
to acknowledge that the rigid employment of standardized 
criteria for diagnosing AD, in fact, restricts our ability to 
fully comprehend the underlying disease process. For exam-
ple, in addition to the characteristic lesions noted above, AD 
is associated with loss of neurons, fibers, and synapses, dis-
ruption of the cortical-laminar architecture, gliosis, prolifera-
tion of dystrophic neurites, and neuro-inflammatory re-
sponses, including microglial cell activation. For unclear 
reasons, these abnormalities are not systematically quanti-
fied, and consequently, they are not routinely incorporated 
into the AD diagnostic equation. At the same time, many 
basic cellular, molecular, biochemical, and structural abnor-
malities in AD overlap with those in other neurodegenerative 
diseases such as dementia with Lewy bodies, fronto-
temporal dementias, and multiple systems atrophy, indicat-
ing that one or two biomarkers might not be sufficient to 
consistently and accurately diagnose AD.  
  Hints that AD could represent a metabolic disease 
emerged from studies showing that the early stages of AD 
were marked by deficits cerebral glucose utilization [10-15], 
and that as the disease progressed, metabolic and physiologi-
cal abnormalities worsened [16, 17]. Subsequently, AD was 
shown to be associated with brain insulin resistance and in-
sulin deficiency, with significant abnormalities in the expres-
sion of genes and activation of kinases that are regulated by 
insulin and insulin-like growth factor (IGF) signaling [4-8]. 
Moreover, it was shown that in AD, progressive declines in 
cerebral glucose utilization, and deficits in insulin signaling 
and insulin-responsive gene expression worsen with severity 
of disease. In particular, insulin/IGF regulated genes, includ-
ing choline acetyltransferase, tau, and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), which mediate cho-
linergic/cognitive, neuronal cytoskeletal, and metabolic func-
tions, are suppressed in AD [7]. Insulin resistance mediated 
impairments in energy metabolism lead to oxidative stress, 
generation of reactive oxygen species (ROS), DNA damage, 
and mitochondrial dysfunction, all of which drive pro-
apoptosis, pro-inflammatory, and pro-APP-A cascades. 
Experimental animals in which brain insulin receptor expres-
sion and function were suppressed exhibited cognitive im-
pairment and neurodegeneration with features that overlap 
with AD [18-22].  
  In AD brains, deficits in insulin/IGF signaling are due to 
the combined effects of insulin/IGF resistance and defi-
ciency. Insulin/IGF resistance is manifested by reduced lev-
els of insulin/IGF receptor binding and decreased respon-
siveness to insulin/IGF stimulation, while the trophic factor 
deficiency is associated with reduced levels of insulin poly-
peptide and gene expression in brain and cerebrospinal fluid 
[6-8, 23-25]. In essence, AD can be regarded as a form of 
brain diabetes that has elements of both insulin resistance 
and insulin deficiency. To consolidate this concept, we pro-
posed that AD be referred to as, “Type 3 diabetes” [7, 8].  
INSULIN AND INSULIN-LIKE GROWTH FACTOR 
ACTIONS IN THE BRAIN 
  In the central nervous system (CNS), insulin and IGF 
signaling play critical roles in regulating and maintaining 
cognitive function. Insulin, IGF-1 and IGF-2 polypeptide and 
receptor genes are expressed in neurons [26-28] and glial 
cells [29-32] throughout the brain, and their highest levels of 
expression are in structures typically targeted by neurode-
generative diseases [33, 34]. Insulin and IGFs regulate a 
broad range of neuronal functions throughout life, from em-
bryonic and fetal development to adulthood. The correspond-
ing signaling pathways are activated by insulin and IGF 
binding to their own receptors, resulting in phosphorylation 
and activation of intrinsic receptor tyrosine kinases. Subse-
quent interactions between the phosphorylated receptors and 
insulin receptor substrate (IRS) molecules promote transmis-
sion of downstream signals that inhibit apoptosis, and stimu-
late growth, survival, metabolism, and plasticity. Anti-
apoptotic mechanisms inhibited by insulin/IGF stimulation 
include BAD (inhibitor of Bcl-2), Forkhead Box O (FoxO), 
glycogen synthase kinase 3 (GSK-3), and nuclear factor 
kappa B (NF- B). GSK-3 regulates Wnt signaling by 
phosphorylating -catenin and thereby targeting it for ubiq-
uitin/proteosome-mediated degradation. Wnt signaling medi-
ates synaptic plasticity in the CNS. Therefore, major func-
tions supported by the insulin/IGF signaling axis include, 
neuronal growth, survival, differentiation, migration, energy 
metabolism, gene expression, protein synthesis, cytoskeletal 
assembly, synapse formation, neurotransmitter function, and 
plasticity [26, 35-38]. Correspondingly, impaired signaling 
through insulin and IGF receptors has dire consequences 
with respect to the structural and functional integrity of the 
CNS.  
IMPAIRED INSULIN/IGF SIGNALING AND TAU 
PATHOLOGY IN AD 
  The major neuronal cytoskeletal lesions that correlate 
with severity of dementia in AD, including neurofibrillary 
tangles and dystrophic neurites, contain aggregated and 
ubiquitinated insoluble fibrillar tau. In other words, tau ac-
cumulation and pathology are the most significant structural 
correlates of dementia in AD [39, 40]. In AD, tau, a micro-AD-Brain Insulin Resistance Therapy  Current Alzheimer Research, 2012, Vol. 9, No. 1    37 
tubule-associated protein, gets hyperphosphorylated due to 
inappropriate activation of several proline-directed kinases, 
including GSK-3. As a result, tau protein misfolds and self-
aggregates into insoluble fibrillar structures [paired helical 
filaments and straight filaments] that form neurofibrillary 
tangles, dystrophic neurites, and neuropil threads [41]. Intra-
neuronal accumulations of fibrillar tau disrupt neuronal cy-
toskeletal networks and axonal transport, leading to synaptic 
disconnection and progressive neurodegeneration [41]. Be-
sides fibrillar tau, pre-fibrillar tau can aggregate, forming 
soluble tau oligomers or insoluble granular tau, which con-
tribute to neurodegeneration by causing synaptic disconnec-
tion and neuronal death [42]. The eventual ubiquitination of 
hyper-phosphorylated tau [43], combined with dysfunction 
of the ubiquitin-proteasome system [44], cause further ac-
cumulation of insoluble fibrillar tau, oxidative stress, and 
ROS generation, which together promote neuronal apoptosis, 
mitochondrial dysfunction, and necrosis in AD [45].  
  Growing evidence suggests that many of the aforemen-
tioned cellular aspects of AD neurodegeneration may be 
caused by brain insulin/IGF resistance [7, 8] which, as in 
other brain insulin-resistance states, results in inhibition of 
downstream pro-growth and pro-survival signaling pathways 
(Fig. 1) [46-49]. Tau gene expression and phosphorylation 
are regulated by insulin and IGF stimulation [50, 51]. In AD, 
brain insulin and IGF resistance result in decreased signaling 
through phosphoinositol-3-kinase (PI3K), Akt [50, 51], and 
Wnt/-catenin [52], and increased activation of glycogen 
synthase kinase 3 (GSK-3) [53-57]. GSK-3 over-
activation is partly responsible for the hyper-phosphorylation 
of tau, which leads to tau misfolding and fibril aggregation 
[58]. In addition, tau hyper-phosphorylation in AD is medi-
ated by increased activation of cyclin-dependent kinase 5 
(cdk-5) and c-Abl kinases [59, 60], and inhibition of protein 
phosphatases 1 and 2A [41, 60, 61]. Besides hyper-
phosphorylation, tau pathology in AD is mediated by im-
paired tau gene expression due to reduced insulin and IGF 
signaling [62]. Consequences include, failure to generate 
sufficient quantities of normal soluble tau protein, vis-a-vis 
accumulation of hyper-phosphorylated insoluble fibillar tau, 
and attendant exacerbation of cytoskeletal collapse, neurite 
retraction, and synaptic disconnection.  
INSULIN/IGF RESISTANCE AND AMYLOID-BETA 
(A) NEUROTOXICITY 
  AD is associated with dysregulated expression and proc-
essing of amyloid precursor protein (APP), resulting in the 
accumulation of APP-A (A) oligomeric fibrils or insolu-
ble larger aggregated fibrils (plaques) that are neurotoxic 
(Fig. 2). Pathophysiologically, increased APP gene expres-
sion, together with altered proteolysis, result in accumulation 
of 40 or 42 amino acid length A peptides that can aggre-
gate. In familial forms of AD, mutations in the APP, prese-
nilin 1 (PS1), and PS2 genes, or inheritance of the Apolipro-
tein E 4 (ApoE- 4) allele, are responsible for increased 
synthesis and deposition of A peptides in the brain. How-
ever, in sporadic AD, which accounts for 90% or more of the 
cases, the causes of A accumulation and toxicity are still 
under intense investigation. Over the past few years, interest 
in the role of impaired insulin/IGF signaling as either the 
cause or consequence of dysregulated APP-A expression 
and protein processing has grown.  
  The concept that A toxicity causes insulin resistance, 
and the opposing argument that brain insulin resistance with 
attendant oxidative stress and neuro-inflammation promotes 
A accumulation and toxicity are both supported by experi-
mental data. For example, studies have established that insu-
lin stimulation accelerates trafficking of A from the trans-
Golgi network, where it is generated, to the plasma mem-
brane, and that insulin stimulates A extracellular secretion 
[63] and inhibits its intracellular accumulation and degrada-
tion by insulin-degrading enzyme [64, 65]. Although it re-
mains uncertain as to whether these physiological actions of 
insulin on APP processing contribute to A burden, what is 
apparent is that impaired insulin signaling can disrupt both 
the processing of APP and clearance of A [66]. The accu-
mulation of A exacerbates the problem because A disrupts 
insulin signaling by competing with insulin, or reducing the 
affinity of insulin binding to its own receptor [67, 68]. In 
addition, APP oligomers inhibit neuronal transmission of 
insulin-stimulated signals by desensitizing and reducing the 
surface expression of insulin receptors. Furthermore, intra-
cellular APP-A directly interferes with PI3 kinase activa-
tion of Akt, which leads to impaired survival signaling, in-
creased activation of GSK-3, and hyper-phosphorylation of 
tau. Hyper-phosphorylated tau is prone to misfold, aggre-
gate, and become ubiquitinated, leading to the formation of 
dementia-associated paired-helical filament-containing neu-
ronal cytoskeletal lesions. Since IGF-1 or IGF-2 suppression 
of GSK-3 activity [69] reduces the neurotoxic effects of 
APP [70-73], the neuro-protective properties of these and 
related trophic factors could be exploited for therapeutic pur-
poses in AD.  
INSULIN/IGF RESISTANCE, OXIDATIVE STRESS, 
AND METABOLIC DYSFUNCTION IN AD 
  Insulin and IGF signaling pathways regulate glucose 
utilization, metabolism, and ATP synthesis needed for cellu-
lar homeostasis and dynamic modulation of a broad range of 
functions (Tables 1, 2). Deficits in cerebral glucose utiliza-
tion and energy metabolism occur very early in the course of 
AD, such that they are detectable either prior to, or coinci-
dent with the initial stages of cognitive dysfunction [25, 74, 
75]. These findings lend strong support the concept that im-
pairments in insulin signaling have important roles in the 
pathogenesis of AD [8]. Glucose uptake and utilization in 
brain are dependent upon glucose transport. Glucose trans-
porter 4 (GLUT4) is abundantly expressed along with insulin 
receptors, in medial temporal lobe structures, which notably 
are major targets of AD neurodegeneration. Insulin stimu-
lates GLUT4 gene expression and protein trafficking from 
the cytosol to the plasma membrane to modulate glucose 
uptake and utilization. Therefore, insulin stimulation of 
GLUT4 is critical to the regulation of neuronal metabolism 
and the generation of energy needed for memory and cogni-
tion. Although postmortem brain studies have not detected 
significant reductions in GLUT4 expression in AD [8], the 
well-documented deficits in brain glucose utilization and 
energy metabolism vis-a-vis brain insulin/IGF resistance 
could instead be mediated by impairments in GLUT4 traf-
ficking between the cytosol and plasma membrane. 38    Current Alzheimer Research, 2012, Vol. 9, No. 1  Suzanne M. de la Monte 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Roles of brain insulin deficiency and brain insulin resistance in Tau pathology. Tau protein is normally regulated by insulin and IGF 
signalling. Insulin deficiency [effective trophic factor withdrawal] and insulin resistance lead to the over-activation of kinases and inhibition 
of phosphatases, which result in hyper-phosphorylation of tau. Attendant increased oxidative stress leads to ROS generation and ubiquitina-
tion, followed by misfolding of Tau. Misfolded tau aggregates and forms insoluble twisted fibrils that are neurotoxic and mediate dementia-
associated neuropathological processes, i.e. neurofibrillary tangle formation, proliferation of dystrophic neuritis and neuropil threads, and 
synaptic disconnection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Brain insulin resistance and APP-A deposition and toxicity. Brain insulin resistance caused by peripheral insulin resistance dis-
eases or primary toxic and neurodegenerative processes in the brain promote neuroinflammation and increased expression of APP. 
Throught the action of Beta and Gamma secretases, AbPP is cleaved to generate excessive 40-42 kD APP-A peptides that aggregate and 
form insoluble fibrils and plaques, or oligomers and APP-A-derived diffusible ligands (ADDLs), which are neurotoxic. APP-A oli-
gomers and ADDLs promote oxidative stress and increased activation of kinases that lead to Tau hyperphosphorylation, and its eventual 
ubiquitination, misfolding, and aggregation. APP-A oligomers and ADDLs may also block insulin receptor function and contribute to 
insulin resistance. Carriers of the ApoE e4 allele or Presenilin mutations are predisposed to excessive and abnormal APP cleavage, and 
APP-A accumulation, aggregation, and fibril formation, correlating with increased rates and familial occurrences of AD.  AD-Brain Insulin Resistance Therapy  Current Alzheimer Research, 2012, Vol. 9, No. 1    39 
Table 1.  Metabolic Hypothesis of Alzheimer's Disease-Consequences of Brain Insulin Resistance 
Impairment  Adverse Effect  Role in Alzheimer's Disease 
GLUT4 function  Reduced glucose uptake and utilization  Energy deficits; compromised homeostatic func-
tions, disruption of neuronal cytoskeleton, synap-
tic disconnection 
Insulin receptor function  Decreased signaling through IRS, PI3K-Akt  Reduced neuronal and oligodendroglial survival, 
neuronal plasticity, myelin maintenance 
  Increased activation of GSK-3 and phosphatases 
that negatively regulate insulin signaling 
Increased tau phosphorylation, oxidative stress, 
neuro-inflammation, pro-apoptosis signaling 
Decreased Wnt signaling 
  Reduced insulin-responsive gene expression  Reduced choline acetyltransferase expression --> 
deficits in acetylcholine 
Decreased GAPDH expression, further impair-
ment of glucose metabolism 
Insulin receptor function or hyper-insulinemia  Endothelial cell injury, intimal thickening, and 
vessel wall fibrosis 
Microvascular disease and cerebral hypoperfu-
sion 
Mitochondrial function  Increased oxidative stress, ROS, RNS  DNA damage, lipid peroxidation, energy deficits, 
cell death, increased APP expression, A42 
deposition and fibrillarization 
Myelin maintenance  Myelin breakdown, increased generation of ce-
ramides and other toxic sphingolipids; lipid per-
oxidation; ROS 
Increased neuro-inflammation, oxidative stress, 
pro-apoptosis signaling, further insulin resistance 
White matter atrophy due to fiber and myelin loss 
Insulin/IGF availability   Trophic factor withdrawal  Death or impaired function of insulin/IGF de-
pendent neurons and glial cells 
Hyperglycemia  Accumulation of advanced glycation end-
products 
Disrupts removal of A42 
Abbreviations: GLUT4=glucose transporter 4; IRS= insulin receptor substrate; PI3K= phosphoinositol-3- kinase; GSK-3 = glycogen synthase kinase 3; GAPDH=glyceraldehyde-
3-phosphate dehydrogenase; ROS=reactive oxygen species; RNS=reactive nitrogen species; APP= amyloid- - precursor protein; A 42=amyloid beta peptide-42 amino acids 1-42 
cleavage product; IGF=insulin-like growth factor. 
 
 
Table 2.  Neuropathologic Processes Contributing to Brain Insulin Resistance in Alzheimer's Disease 
Neurodegenerative Disease Process  Mechanism of impairing brain insulin signaling  Consequences in relation to brain insulin signaling 
A42 toxicity  Competes with insulin and reduces affinity of insulin 
binding to its receptor 
APP oligomers desensitize and reduce surface ex-
pression of insulin receptors 
Interferes with PI3K activation of Akt 
Disrupts insulin signaling 
Impairs insulin stimulated neuronal survival and  
plasticity 
Increases GSK-3 activation and tau  
hyperphosphorylation 
Microvascular disease  Cerebral hypoperfusion, hypoxic-ischemic injury  Exacerbates insulin resistance;  
Oxidative stress  DNA damage, lipid peroxidation, fibrillarization of 
oligomeric tau and A42 
Increases neuro-inflammation and pro-inflammatory 
cytokine inhibition of insulin signaling 
Toxic lipids impair signaling through PI3K-Akt 
Transition metal ion accumulations  Mitochondrial dysfunction, oxidative stress, tau and 
APP oligomer fibrillarization  
Impairs glucose uptake and utilization, inhibits insulin 
signaling 
Hyperphosphorylated-ubiquitinated tau  Increases oxidative stress, promotes neuro-
inflammation 
Enhances insulin resistance 
Abbreviations: PI3K= phosphoinositol-3- kinase; GSK-3 = glycogen synthase kinase 3; APP= amyloid- - precursor protein; A 42=amyloid beta peptide-42 amino acids 1-42 
cleavage product 
 
 
 40    Current Alzheimer Research, 2012, Vol. 9, No. 1  Suzanne M. de la Monte 
 
  Deficiencies in energy metabolism tipped by inhibition of 
insulin/IGF signaling increase oxidative stress, mitochon-
drial dysfunction, and pro-inflammatory cytokine activation 
[19, 48, 76]. Oxidative stress leads to increased generation 
and accumulation of reactive oxygen (ROS) and reactive 
nitrogen species (RNS) that attack subcellular components 
and organelles. The resulting chemical modifications, includ-
ing adducts formed with DNA, RNA, lipids, and proteins, 
compromise the structural and functional integrity of neu-
rons. Consequences include, loss of cell membrane func-
tions, disruption of the neuronal cytoskeleton with dystrophy 
and synaptic disconnection, deficits in neurotransmitter func-
tion and neuronal plasticity, and perturbation of signal trans-
duction and enzymatic pathways required for energy metabo-
lism, homeostasis, and neuronal survival.  
  Mitochondrial dysfunction exacerbates electron transport 
chain function, reducing ATP generation and increasing 
ROS production. Pro-inflammatory cytokine activation is 
mediated by neuro-inflammatory responses in microglia and 
astrocytes. Neuro-inflammation increases oxidative stress, 
organelle dysfunction, and pro-apoptosis signaling. Moreo-
ver, stresses caused by inhibition of insulin/IGF signaling 
stimulate APP gene expression [77] and aberrant APP 
cleavage, with attendant increased APP-A deposition and 
toxic fibril formation in the brain [73, 78-82]. Persistence of 
oxidative stress leads to constitutive activation of kinases 
e.g. GSK-3, that promote aberrant hyper-phosphorylation of 
tau. Therefore, in AD, oxidative stress and impairments in 
energy metabolism stemming from brain insulin/IGF resis-
tance quite likely contribute to neuronal loss, APP toxicity, 
tau cytoskeletal pathology, and neuro-inflammation [7, 26, 
83]. The degree to which these abnormalities can be effec-
tively targeted for therapy in AD is actively under investiga-
tion. 
MECHANISMS OF BRAIN INSULIN/IGF RESIS-
TANCE IN NEURODEGENERATION [FIG. 3] 
  Although aging is clearly the dominant risk factor for 
AD, growing evidence suggests that peripheral insulin resis-
tance with obesity, T2DM, metabolic syndrome (dyslipi-
demic states), and non-alcoholic steatohepatitis (NASH) 
mediate brain insulin/IGF resistance, and thereby contribute 
to the pathogenesis of mild cognitive impairment (MCI), 
dementia, and AD [5, 6, 25, 26, 50, 51, 84-87]. However, 
only within the past several years has this field greatly ex-
panded due to input from both human and experimental ani-
mal studies that produced new information about the causes 
and consequences of brain insulin resistance and deficiency 
in relation to cognitive impairment [7, 8, 22, 83, 88-90]. 
Concerns over the role of peripheral insulin resistance as a 
mediator of cognitive impairment and sporadic AD have 
been ratcheted up by globalization of the obesity epidemic 
[1, 84]. In order to develop logical and novel approaches for 
treating and preventing neurodegeneration based on the brain 
insulin resistance hypothesis, three main questions must be 
addressed: 1) Do T2DM and other peripheral insulin resis-
tance states cause neurodegeneration, including AD? 2) Do 
T2DM and other peripheral insulin resistance disease states 
principally serve as co-factors in the pathogenesis of cogni-
tive impairment and neurodegeneration? or 3) Do T2DM and 
AD fundamentally represent the same disease processes oc-
curring in different target organs and tissues? These ques-
tions are addressed below. 
Contributions of Obesity and T2DM to Cognitive Im-
pairment and Neurodegeneration 
  Epidemiologic studies demonstrated that individuals with 
glucose intolerance, deficits in insulin secretion, or T2DM 
have a significantly increased risk for developing mild cog-
nitive impairment (MCI) or AD-type dementia. Longitudinal 
studies provided further evidence that T2DM [91, 92] and 
obesity/dyslipidemic disorders [93] were correlated with 
later development of MCI, dementia, or AD [91, 94-99]. 
However, one study showed that obesity itself, with or with-
out superimposed T2DM, increased the risk for MCI, AD, or 
other forms of neurodegeneration [100], suggesting that sys-
temic factors related to obesity, other than T2DM, can pro-
mote neurodegeneration. On the other hand, although a rela-
tively high percentage of individuals with MCI or dementia 
have T2DM, peripheral insulin resistance, or obesity, the 
vast majority of patients with AD do not have these diseases. 
To gain a better understanding of the contributions of T2DM 
and obesity to neurodegeneration, attention must be given to 
postmortem human and experimental animal studies. 
  In general, the arguments made in favor of the concept 
that T2DM or obesity causes AD are not founded; however, 
the concept that peripheral insulin resistance disease states 
contribute to cognitive impairment and AD pathogenesis or 
progression does have a sound basis. Against a causal role 
are the findings that, postmortem human brain studies dem-
onstrated no significant increase in AD diagnosis among 
diabetics [101], and similarly abundant densities of senile 
plaques and rates of neurofibrillary tangle pathology were 
observed in subjects with T2DM compared with normal aged 
controls, although peripheral insulin resistance was more 
common in AD than with normal aging [102]. Since neurofi-
brillary tangles and dystrophic neurites are hallmarks of AD 
and correlate with severity of dementia, the abovementioned 
findings in human postmortem studies indicate that T2DM 
alone is not sufficient to cause AD. On the other hand, in 
experimental mouse and rat models, chronic high fat diet 
(HFD) feeding and diet induced obesity (DIO) with associ-
ated T2DM, do cause cognitive impairment with deficits in 
spatial learning and memory [103, 104]. Moreover, experi-
mental obesity with T2DM causes mild brain atrophy with 
brain insulin resistance, neuro-inflammation, oxidative 
stress, and deficits in cholinergic function [105, 106]. An 
important qualifier about these studies is that the associated 
brain abnormalities were typically modest in severity, and 
they were devoid of the most important structural lesions that 
characterize AD, i.e. neurofibrillary tangles. Therefore, ob-
servations both in humans and experimental models suggest 
that while obesity or T2DM can be associated with cognitive 
impairment, mild brain atrophy, and a number of AD-type 
biochemical and molecular abnormalities in brain, including 
insulin resistance and oxidative stress, they do not cause sig-
nificant AD pathology. Instead, the findings suggest that 
T2DM, obesity, and probably other peripheral/systemic insu-
lin resistance states serve as co-factors contributing to the 
pathogenesis or progression of neurodegeneration. The sig-AD-Brain Insulin Resistance Therapy  Current Alzheimer Research, 2012, Vol. 9, No. 1    41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). High caloric intake and/or chronic low-level nitrosamine exposures [through diet, smoking, agriculture], promote fatty liver disease 
(steatohepatitis) that progresses due to injury and inflammation, eventually leading to hepatic insulin resistance. The same poor physiological 
states also promote obesity, diabetes mellitus, and other peripheral insulin resistance diseases. Toxic lipids, including ceramides, made in the 
liver, get released into the circulation, cross the blood-brain barrier, and cause brain insulin resistance, inflammation, energy failure, toxicity, 
and local production of toxic ceramides. The end result is progressive neurodegeneration, including Alzheimer’s disease.  
 
nificance of these results is that therapeutic strategies de-
signed to treat T2DM, obesity, and systemic insulin resis-
tance could help slow the progress or reduce the severity of 
AD, but they will not likely prevent it altogether. Corre-
spondingly, a number of studies have already demonstrated 
that treatment with hypoglycemic or insulin sensitizer agents 
can be protective in reducing the incidence and severity of 
AD brain pathology [107]. 
Factors Mediating Cognitive Impairment and Neurode-
generation in Disease States with Systemic Insulin Resis-
tance 
Vascular Factors 
  The mechanisms by which T2DM, obesity, and periph-
eral insulin resistance contribute to MCI, dementia, and neu-
rodegeration are not fully understood. Factors under investi-
gation include, chronic hyperglycemia, peripheral insulin 
resistance, oxidative stress, accumulation of advanced glyca-
tion end-products, increased expression and activation of 
insulin degrading enzyme, increased production of pro-
inflammatory cytokines, and cerebral microvascular disease 
[98]. By far, the contributions of cerebral microvascular dis-
ease to AD progression are easiest to sort out, and conse-
quently have been recognized for years. In this regard, post-
mortem studies demonstrated that similar degrees of demen-
tia occurred in subjects who either had severe AD neuropa-
thology or moderate degrees of AD plus chronic ischemic 
encephalopathy. The nature of ischemic encephalopathy 
ranged from multifocal ischemic lesions, to infarcts strategi-
cally localized in structures ordinarily targeted for AD neu-
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white matter fibers [108]. Magnetic resonance imaging 
[MRI] studies have lent support to this concept by showing 
that, among older adults, the risks of developing lacunes and 
atrophy of medial temporal lobe structures [hippocampal and 
amygdalar], i.e. targets of AD neurodegeneration, increase 
with duration and progression of T2DM [109]. Apart from 
diabetes-associated arteriosclerosis, factors that could con-
tribute to cerebrovascular disease and increased risk of AD 
progression include, hyperinsulinemia and inheritance of the 
ApoE-4 allele. Although controversial, both insulin resis-
tance and hyperinsulinemia are injurious to blood vessels, 
causing intimal thickening, scarring, and leakiness [110-
115]. Furthermore, postmortem brain studies have shown 
compounded risk for developing AD among hyperinsuline-
mic diabetics who also carry at least one ApoE-4 allele, and 
relative resistance to AD among non-diabetic, ApoE4-4 
negative individuals. The latter group had significantly lower 
densities of APP-A plaques and neurofibrillary tangles 
compared with ApoE-4 positive, hyperinsulinemic diabet-
ics. 
Role of Neurotoxic Lipids Generated in Peripheral Organs 
and Tissues 
  Apart from chronic ischemic injury and cerebral mi-
crovascular disease, data generated by independent studies 
suggest that cognitive impairment and neuropsychiatric dys-
function correlate more with hepatic steatosis and insulin 
resistance than obesity or T2DM [116-122]. For example, 
neurocognitive deficits and brain insulin resistance occurred 
in experimental models of chronic HFD feeding in which the 
mice and rats also developed visceral obesity with hepatic 
steatosis or steatohepatitis. In addition, toxin exposure mod-
els that cause steatohepatitis and hepatic insulin resistance in 
the absence of obesity, also caused neurodegeneration and 
cognitive impairment [22, 83, 105, 106, 123, 124]. There-
fore, we considered the role of hepatic insulin resistance as a 
mediator of neurodegeneration.  
  Hepatic insulin resistance dysregulates lipid metabolism, 
resulting in increased oxidative and ER stress, and mito-
chondrial dysfunction. Mechanistically, physiologic insulin 
stimulation promotes lipogenesis, which increases triglyc-
eride storage in the liver [125, 126]. However, in disease 
states associated with injury and inflammation, hepatocytes 
sustain ER stress, oxidative damage, mitochondrial dysfunc-
tion, and lipid peroxidation, which together promote hepatic 
insulin resistance [125, 127]. Hepatic insulin resistance 
stimulates lipolysis [128], and lipolysis leads to increased 
generation of toxic lipids e.g. ceramides, which further im-
pair insulin signaling, mitochondrial function, and cell vi-
ability [127, 129, 130].  
  Ceramides are lipid signaling molecules [131] that cause 
insulin resistance [132-134] by activating pro-inflammatory 
cytokines [131, 135, 136] and inhibiting signal transduction 
through PI3 kinase-Akt [137-140]. In diet-induced obesity 
(DIO) models, insulin resistance develops in adipocytes, 
along with locally and peripherally increased levels of cera-
mides [131, 141-145]. With experimental steatohepatitis 
caused by DIO or low-level nitrosamine exposure, hepatic 
and peripheral insulin resistance are also accompanied by 
locally and peripherally increased ceramide levels [22, 83, 
105, 123, 124]. The compilation and integration of data from 
all of these studies led to the realization that cognitive im-
pairment with brain insulin resistance and neurodegeneration 
was principally correlated with hepatic steatosis-associated 
insulin resistance rather than obesity or T2DM per se. This 
point led to the hypothesis that, in the settings of obesity, 
T2DM, and various peripheral insulin resistance states, cog-
nitive impairment is mediated via a liver-brain axis of neu-
rodegeneration [33, 34, 146]. 
  In essence, the key factors linking peripheral insulin re-
sistance states to cognitive impairment with neurodegenera-
tion and brain insulin resistance, are the increased generation 
of ceramides in liver, and increased levels of ceramide in 
peripheral blood. In hepatic dyslipidemic states, ceramide 
levels increase due to elevated biosynthesis or reduced deg-
radation from altered gene expression and enzymatic activ-
ity. In vitro experiments showed that ceramides are indeed 
neurotoxic and cause neuronal insulin resistance, oxidative 
stress, and molecular and biochemical abnormalities similar 
to those that occur in AD [147]. Moreover, parenteral ad-
ministration of cytotoxic ceramides produces sustained im-
pairments in spatial learning and memory with neurodegen-
eration and brain insulin/IGF resistance, similar to the effects 
of DIO with T2DM and NASH [146]. Therefore, we hy-
pothesize that toxic lipids, in particular ceramides, generated 
in livers with hepatic insulin resistance caused by obesity, 
T2DM, metabolic syndrome, chronic alcohol abuse, or low-
dose nitrosamine exposure, are the principal mediators of 
neurodegeneration, and that they exert their neurotoxic ef-
fects in the CNS via a liver-brain axis [146]. Mechanisti-
cally, cytotoxic ceramides generated in livers with steatohe-
patitis, insulin resistance, and ER stress, traffic through the 
circulation, and due to their lipid soluble nature, they cross 
the blood-brain barrier and exert neurotoxic and neurodegen-
erative effects by impairing insulin signaling. Preliminary 
studies demonstrated that treatment with chemical inhibitors 
of ceramide biosynthesis enhances insulin sensitivity, and 
treatment with peroxisome proliferator-activated receptor 
(PPAR) agonists, which improve insulin responsiveness and 
reduce oxidative stress [83, 148-150], decrease hepatic ce-
ramide generation, serum ceramide levels, cognitive impair-
ment, and neurodegeneration in models of DIO with T2DM 
and steatohepatitis [151]. Therefore, in addition to microvas-
cular disease, we propose that peripheral insulin resistance 
diseases contribute to neurodegeneration, including AD, by 
increasing production of neurotoxic ceramides that cause 
brain insulin resistance. This mechanism could account for 
the parallel epidemics of T2DM, obesity, and AD [1]. 
Alzheimer's is a Brain Diabetes Mellitus [Type 3 Diabe-
tes] 
  A convincing argument could be made that AD, in its 
pure form, represents a brain form of diabetes mellitus [7, 8] 
since, AD is associated with progressive brain insulin resis-
tance in the absence of T2DM, obesity, or peripheral insulin 
resistance [7, 8, 89, 90]. Moreover, postmortem studies dem-
onstrated that the molecular, biochemical, and signal trans-
duction abnormalities in AD are virtually identical to those 
that occur in T1DM and T2DM [7, 8, 91, 152-156]. The 
strongest evidence lending support to this concept comes 
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istered intracerebroventricular injections of streptozotocin, a 
pro-diabetes drug. The treated rats developed cognitive im-
pairment with deficits in spatial learning and memory, brain 
insulin resistance and insulin deficiency, and AD-type neu-
rodegeneration, but not diabetes mellitus [22, 157-160]. In 
contrast, i.p. or i.v. administration of streptozotocin causes 
diabetes mellitus with relatively mild degrees of hepatic stea-
tosis and neurodegeneration [157, 161-163]. These findings 
indicate that exposure to a single pro-diabetes drug can cause 
organ/tissue degeneration characterized by impairments in 
insulin signaling and energy metabolism, with attendant in-
creased oxidative stress, mitochondrial dysfunction, and cell 
death. However, disease spectrum and target organ involve-
ment are governed by dose and route of drug administration. 
  Despite overwhelmingly convincing data, relevance of 
this specific model to the human condition remains open to 
question because streptozotocin is generally not available to 
humans. On the other hand, this hypothesis is rendered more 
appealing by the realization that streptozotocin is a nitrosa-
mine-related compound, and that over the past several dec-
ades, Western societies have been assaulted by continuous 
and increasing exposures to environmental and food-related 
nitrosamines. We conducted experiments to determine if 
low, sub-mutagenic doses of nitrosamine compounds that are 
found in food, e.g. N-nitrosodiethylamine (NDEA), could 
cause insulin resistance diseases. Alarmingly, those studies 
showed that low-dose and very limited exposures to NDEA 
cause T2DM, non-alcoholic steatohepatitis, visceral obesity, 
cognitive impairment, and AD-type neurodegeneration with 
peripheral, hepatic, and brain insulin resistance [123, 124], 
similar to the effects of streptozotocin. Moreover, the ad-
verse effects of NDEA on neuro-cognitive deficits, periph-
eral, hepatic, and brain insulin resistance, steatohepatitis, and 
neurodegeneration were exacerbated by chronic high fat diet 
feeding [164, 165]. Therefore, depending on the structure of 
the compound, dose, and route of administration, exposures 
to nitrosamine-related chemicals can cause insulin resistance 
diseases in multiple different target organs, including brain. 
In addition to providing evidence that the relatively recent 
epidemics of sporadic AD, T2DM, and non-alcoholic steato-
hepatitis/metabolic syndrome could be mediated by envi-
ronmental or dietary exposures [1], these studies demonstrate 
that insulin resistance diseases with essentially the same un-
derlying cellular abnormalities, can develop in various or-
gans and tissues. This phenomenon could account for the 
overlapping increases in prevalence rates of various insulin 
resistance diseases within the past several decades, as well as 
the very frequent but incomplete overlap between AD and 
obesity, T2DM, and NASH [102], which did not exist prior 
to 1980, and is not accounted for by aging of the population 
[1]. 
Strategies for Early Diagnosis and Evaluation of Treat-
ment Responses -Neuroimaging 
  The combined use of clinical and postmortem assess-
ments provides the most accurate means of diagnosing AD. 
However, further advancements in detection, monitoring and 
treatment, particularly in the early stages of disease, will not 
likely occur without additional objective and standardized 
tools [166]. Although magnetic resonance imaging [MRI] of 
the brain can be used to track progression of medial temporal 
lobe atrophy as mild cognitive impairment (MCI) advances 
toward AD, and AD worsens in stage and severity [167], the 
diagnostic specificity of such a single-pronged approach is 
limited [168]. On the other hand, emerging evidence sug-
gests that assessments of brain function, including flow and 
metabolism, combined with structural abnormalities may 
substantially improve diagnostic accuracy and help monitor 
disease progression. For example, the progressive cortical 
hypo-perfusion and hypo-metabolism that accompany ad-
vancement of AD, can be readily detected by single photon 
emission computed tomography (SPECT]) [169, 170] and 
positron-emission tomography (PET) [12, 168, 171-174]. 
Furthermore, tracking deficits in flow and metabolism to 
specific brain regions that are targeted by AD could help 
improve diagnostic accuracy. In this regard, detecting meta-
bolic and blood flow impairments in the posterior cingulate 
and parietal-temporal cortices would support an AD diagno-
sis [175]. On the other hand, it is unlikely that neuroimaging 
will ever stand alone as a diagnostic tool since this approach 
cannot replace sophisticated clinical assessments that detect 
subtle neurobehavioral abnormalities that help distinguish 
one form of neurodegeneration from another. In addition, the 
fact that several types neurodegenerative disease, including 
ischemic encephalopathy, can overlap with the structural 
targets in AD, supports the argument that, right now, we 
need better, non-invasive diagnostic measures that go be-
yond, but also compliment neuroimaging assessments of 
brain structure, flow and metabolism.  
  Functional MRI adds an important diagnostic dimension 
because it combines neuro-imaging with assessments of 
brain metabolic responses to stimuli, including insulin [171, 
176]. In addition, the joint use of PET with diffusion tensor 
imaging to correlate severity of cortical hypo-metabolism 
with loss of white matter integrity [177] holds promise in 
terms of improving our ability to diagnose and monitor pro-
gression of AD, based on objective stage-dependent struc-
tural, functional, and metabolic criteria for neurodegenera-
tion. Detection of leukoaraiosis and white matter high inten-
sity lesions in diabetics could help predict individuals at risk 
for cognitive impairment and dementia [178]. The expecta-
tion is that ultimately, the use of sensitive functional neuroi-
maging, combined with structural imaging and multimodal 
biomarker panels, will improve diagnostic accuracy and fa-
cilitate evaluation of treatment effects in the early stages of 
AD [179-181].  
Strategies for Early Diagnosis and Evaluation of Treat-
ment Responses - Cerebrospinal Fluid and Peripheral 
Blood Biomarkers 
  Biomarkers for detecting and diagnosing severity of AD 
have largely been focused on measuring APP-A, tau, and 
phospho-tau in cerebrospinal fluid (CSF) [182, 183]. 
Changes in CSF levels of A-42, total tau, and phospho-tau 
[181] can help predict progression from MCI to dementia 
[184], or aid in establishing a diagnosis of AD [185]. At least 
in some studies, the sensitivity and specificity of these CSF 
biomarkers approach 85% for diagnosing AD and distin-
guishing AD from MCI [175, 179, 183, 186-188]. However, 
inter-laboratory variability and the lack of standardization 
measures to ensure quality assurance, have limited broad and 
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at the core of the neurodegenerative process is protein mis-
folding and aggregation, biomarkers are needed to identify 
and quantify oligomeric neurotoxic aggregates of tau and 
A-42 [191]. Beyond these issues lay concerns that by limit-
ing our considerations to basically two biomarkers, we have 
failed to significantly advance the field. In fact, for various 
reasons, this rather circumscribed approach has not proven to 
be sufficiently sensitive to render an accurate diagnosis of 
AD or predict outcomes of MCI in a case-by-case basis 
[192]. 
  Given the spectrum of other significant abnormalities that 
precede or accompany AD, it would seem more prudent to 
incorporate a broader spectrum of biomarkers into a multi-
modal panel to better characterize AD stage and progression 
[193]. For example, indices of oxidative stress, neuro-
inflammation, mitochondrial dysfunction, metabolic de-
rangements, and impaired insulin/IGF signaling should be 
integrated into the overall equation to improve the sensitivity 
and specificity of diagnosing AD [3, 193, 194]. The use of 
multi-analyte profiling would enable efficient capture of data 
and tracking of abnormalities as the biomarker indices shift 
with disease progression [195]. For example, CSF pro-
inflammatory cytokine levels are elevated in the early stages 
of AD, as well as in MCI [196]. Similarly, MCI and early-
stage AD are marked by increased oxidative stress with 
raised levels of redox-active iron in CSF [197]. These find-
ings suggest that neuro-inflammatory and oxidative stress 
responses should be evaluated to help gauge the presence, 
severity, and progression of neurodegeneration in the early 
stages of disease. At the same time, it could be argued that 
these factors may be initially responsible for propagating the 
neurodegeneration cascade, and therefore should be consid-
ered as potential therapeutic targets. Although, in later stages 
of disease, oxidative stress and pro-inflammatory biomark-
ers, whether in plasma or CSF, seem to lack diagnostic util-
ity [198], the persistently elevated CSF levels of oxidized 
coenzyme Q-10 and 8-hydroxy-2'-deoxyguaniosine suggest 
that mitochondrial and DNA oxidative damage mediate AD 
progression [199, 200], and therefore could be targeted 
therapeutically to slow the advancement of AD. 
  Peripheral blood biomarkers in lymphocytes and plasma 
hold some promise as non-invasive surrogate screening 
tools, and may provide a means to study populations at in-
creased risk for developing AD [201]. For example, abnor-
malities in APP-A cleavage are detectable in peripheral 
blood lymphocytes in AD. In addition, protein kinase C 
(PKC), which has an important role in stimulating APP-
A peptide formation and tau hyperphosphorylation, could 
serve as a peripheral blood biomarker, since conformational 
changes in the PKC enzyme that promote AD pathology are 
detectable in erythrocytes [202]. Similarly, from the perspec-
tive that neuro-inflammation promotes neurodegeneration, it 
may be possible to use elevated serum levels of acute phase 
proteins and pro-inflammatory cytokines to help gauge the 
likelihood of progressing from MCI to dementia, particularly 
in the early stages of disease when neuro-inflammation is 
likely to be a relevant biomarker [203]. However, the utility 
of peripheral blood cytokine and trophic factor levels as di-
agnostic aids for distinguishing AD from MCI has proven 
unacceptable due to disease heterogeneity and the multiple 
co-factors contributing to neurodegeneration [204]. The 
combined use of serum and CSF to measure APP-A pep-
tides, total tau, and phosphorylated tau has been proposed 
for diagnosis and monitoring responses to treatment [205]. 
But, this approach could be flawed because drug treatments 
may not produce detectable shifts in serum levels of APP-
A or tau [206]. Again, these limitations highlight the im-
portance of establishing multi-pronged diagnostic ap-
proaches that will include CSF and serum bio-assays, to-
gether with functional and structural neuro-imaging studies 
to diagnose AD and predict progression from MCI to AD 
[183]. 
   In designing comprehensive CNS neurodegenerative dis-
ease biomarker panels, it should also be possible to capitalize 
on the concept that AD is a metabolic disease that closely 
resembles a brain form of diabetes mellitus. CSF assays 
could be used to detect brain insulin resistance and insulin 
deficiency, while peripheral blood studies could be used to 
simultaneously assess peripheral insulin resistance status 
marked by reduced glucose tolerance, hyperglycemia, hyper-
insulinemia, accumulation of advanced glycation endpro-
ducts, and reactive oxygen species [178]. For example, AD 
is associated with significantly reduced CSF insulin levels, 
but in some cases, hyper-insulinemia as well [178, 207]. The 
finding that plasma and CSF insulin levels may be signifi-
cantly elevated in AD relative to normal aged controls after 
an oral glucose load, but not at basal or post-fasting time 
points [11] suggests that insulin resistance in AD should be 
assessed with dynamic functional rather than static assays. 
This concept is reinforced by the fact that the extent of these 
abnormalities correlates with severity of dementia, particu-
larly among individuals who lack the ApoE-4 allele [208]. 
On the other hand, not all studies have been able to confirm 
reduced CSF insulin levels in AD [209]. Finally, in AD, CSF 
levels of IGF binding proteins [IGFBP] 2 and 6 [210], and 
both CSF and serum levels of IGF-1 [211] are elevated rela-
tive to control [210]. This suggests that, in addition to insulin 
resistance, AD is associated with IGF-1 resistance in the 
brain, and therefore attending to just one or the other signal-
ing pathway will likely not be sufficient to arrest disease.  
  Besides insulin and IGFs, previous studies have sug-
gested roles for impaired expression and function of other 
CNS trophic factors in the context of neurodegeneration. For 
example, the role of nerve growth factor [NGF] as a potential 
target for both diagnosis and treatment arose because NGF 
promotes survival and function of basal forebrain cholinergic 
neurons which undergo neurodegeneration early in the 
course of AD [212, 213]. However, interest in this concept 
initially waned, in part due to the finding that CSF and/or 
brain levels of NGF were not abnormal in AD [214-216]. 
Although subsequent studies utilizing more sensitive ap-
proaches, were able to detect significantly elevated levels of 
NGF in AD CSF or ventricular fluid [217, 218], similar ab-
normalities were observed in vascular dementia as well 
[219].  
  Other trophic factors of note include, transforming 
growth factor beta (TGFbeta) modulates responses to injury 
in the brain, acidic fibroblast growth factor (aFGF), which 
modulates cellular proliferation and differentiation, and neu-
ronal thread protein (NTP), which accumulates in AD brains, 
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pho-tau [62, 220-222]. With regard to TGFbeta, CSF studies 
have produced mixed results with some reports showing no 
change [223, 224], and others demonstrating significantly 
elevated levels of TGFbeta [225, 226] in AD relative to con-
trols. In two independent studies, elevated choroid plexus 
and CSF levels of aFGF distinguished AD from normal ag-
ing [227, 228]. Finally, a number of studies published in the 
last 10-15 years demonstrated the utility of neuronal thread 
protein (NTP) as a potential CSF biomarker of AD [229-
234]. However, the lack of widely available reagents and 
poor understanding of its connection to AD, prevented its 
incorporation into mainstream concepts about neurodegen-
eration. Nonetheless, the aggregate findings with regard to 
AD-associated proteins other than phospho-tau and APP-
A, suggest that assays of NGF, TGFbeta, aFGF, and pos-
sibly NTP in CSF or ventricular fluid could be employed in 
multi-biomarker panels for detecting AD or monitoring re-
sponses to therapy.  
  Ideally, it would be most convenient and least costly to 
utilize peripheral blood or urine based biomarker assays to 
detect neurodegeneration. Such minimally invasive ap-
proaches have been considered and are still under scrutiny. 
For example, elevated levels of NTP are detectable in urine 
of AD patients, beginning early in the course of disease [230, 
235-238]. Serum-based immunoassays have been used to 
detect oxidative injury pertinent to APP-A and phospho-
tau accumulations [198] or insulin/IGF-related metabolic 
impairments [210, 211] in AD brains. Paralleling observa-
tions with respect to CSF, investigators detected elevated 
levels of aFGF in AD sera [227]. However, attempts to ex-
tend these types of analyses to all potential biomarkers may 
not be feasible without substantial technical improvements in 
the sensitivity and specificity of detection methods. For ex-
ample, even with regard to established abnormalities in AD, 
e.g. GLP-1, neuropeptide Y, and ghrelin-growth hormone 
expression, the levels detected in serum do not reliably dis-
tinguish patients with neurodegeneration from those with 
normal aging [239]. Another potential hurdle in designing 
serum-, plasma- or urine-based assays of AD is that certain 
neurodegeneration-associated abnormalities, even those that 
can be detected in CSF, may not be detectable in extra-CNS 
body fluids. Future studies should be directed toward corre-
lating AD biomarker assay data from CSF, peripheral blood, 
and urine to establish non-invasive means of detecting and 
monitoring AD neurodegeneration and responses to therapy. 
Rectifying Dementia Based on the Brain Insulin Resis-
tance/Insulin Deficiency Disease Model to Prevent, Re-
tard, Halt, and Cure AD-Type Neurodegeneration 
  The volume of literature supporting the concept that AD 
is associated with deficits in energy metabolism, glucose 
utilization, and insulin/IGF responsiveness in the brain has 
grown rapidly, causing the paradigm of AD pathogenesis to 
shift away from the overwhelmingly dominant amyloid and 
taupathy hypotheses. The attractiveness of the meta-
bolic/brain insulin resistance hypothesis is that the impair-
ments in brain insulin and IGF signaling caused by insu-
lin/IGF resistance, together with the eventual depletion of 
trophic factors, could account for nearly all other abnormali-
ties that occur in AD, including increased oxidative stress 
and ROS generation, mitochondrial dysfunction, cell death, 
loss of synaptic plasticity, deficits in cholinergic homeosta-
sis, increase expression of APP, hyper-phosphorylation of 
tau, compromised myelin maintenance, and neuroinflamma-
tion. Another attractive feature of the metabolic/brain insulin 
resistance hypothesis is that it demystifies the pathophysiol-
ogy of AD by relating it to other well-recognized systemic 
diseases, i.e. diabetes mellitus, non-alcoholic steatohepatitis, 
and metabolic syndrome. If indeed these diseases are all es-
sentially the same except they involve different principal 
target organs, then the treatment and prevention approaches 
would also be similar or possibly the same. This concept is 
not far-fetched. For example, atherosclerosis can preferen-
tially affect different major blood vessels and result in differ-
ent patterns and distributions of tissue injury and disease, yet 
no one would regard each spectrum of disease as having a 
distinct pathogenesis. However, what does require further 
research is determining the degrees to which brain insulin 
resistance, cognitive impairment, and neurodegeneration are 
consequential to peripheral insulin resistance diseases, par-
ticularly type 2 diabetes mellitus (T2DM), obesity, and 
metabolic syndrome, or whether they constitute an intrinsic 
disease process equivalent to a brain form of diabetes melli-
tus. Although the above discussions culling human and ex-
perimental animal studies lend support to both arguments, 
epidemiological, clinical, and postmortem studies clearly 
show that sporadic AD develops primarily in the absence of 
obesity and T2DM. Nonetheless, with strong data coming 
from both points of view, it is likely that both concepts are 
correct. In fact, the existence of primary and secondary 
mechanisms of brain insulin resistance and neurodegenera-
tion would help explain the heterogeneity of the AD pheno-
type. In the ensuing discussion of potential therapeutic tar-
gets for AD, emphasis will be placed on how current strate-
gies address the brain insulin resistance/metabolic impair-
ments in AD. 
Potential Therapeutic Targets and Strategies for AD 
  Regarding potential strategies for treating sporadic AD, 
the major issues to be considered are: 1) Does hyper-
insulinemia in obesity and T2DM cause oxidative stress and 
neurodegeneration; 2) does peripheral insulin resistance lead 
to increased cerebral micro-vascular disease and thereby 
cause brain atrophy and degeneration? 3) How do dyslipi-
demic states associated with T2DM, obesity, and non-
alcoholic steatohepatitis (NASH) contribute to neurodegen-
eration? 4) does the overlap among T2DM, NASH, obesity, 
and neurodegeneration/AD reflect a single pathophysiologi-
cal process that causes variable degrees of metabolic dys-
regulation in different target organs and tissues, e.g. brain, 
liver, and skeletal muscle? 5) To what extent is AD-type 
neurodegeneration primarily mediated by intrinsic impair-
ments of brain insulin/IGF signaling, versus secondary ef-
fects of peripheral organ insulin resistance diseases, e.g. 
T2DM? In many respects, the appreciation that AD funda-
mentally represents a metabolic disease associated with the 
same molecular, biochemical, and cell signaling abnormali-
ties identified in peripheral insulin resistance diseases, could 
simplify future approaches to treatment and prevention (Ta-
ble  3). For example, pharmacotherapeutic concepts devel-
oped for T2DM and NASH may be adaptable to AD. Al-
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Table 3.  Therapeutic Targets for Alzheimer's Disease Based on Metabolic Hypothesis 
Target Agent  Mechanism  of  Action 
Glutamate excitotoxicity  NMDA glutamatergic receptor antoginist  Helps restore brain metabolic functions 
Cholinergic deficiency  Acetylcholinesterase inhibitor  May stimulate production of trophic factors, e.g IGF-1; 
protects against glutamate neurotoxicity; activates PI3K-
Akt, promoting neuronal survival 
A42 accumulation and fibrillari-
zation 
Gamma secretase inhibitor drugs (Notch sparing); 
BACE1 inhibitors to reduce cleavage and production of 
toxic peptides 
Reduces insulin resistance, enhances PI3K-Akt signal-
ing; reduces GSK-3 activity resulting in decreased tau 
phosphorylation 
Tau hyperphosphorylation  GSK-3 and protein phosphatase 2A inhibitors  Reduces oxidative stress, helps restore insulin respon-
siveness 
Insulin deficiency  Insulin therapy-intranasal 
Incretins, e.g. GLP-1 to stimulate insulin 
Maintains survival and function of cells requiring insulin 
stimulation; supports glucose uptake, brain metabolism 
and neuronal plasticity; Decreases APP burden and tau 
hyperphosphorylation; Enhances cognition 
Hyperglycemia  Antihyperglycemic agents-biguanides  Enhance glucose uptake and insulin receptor sensitivity 
Insulin resistance  Insulin sensitizers, e.g. PPAR agonists  Enhance glucose uptake and insulin receptor sensitivity; 
anti-inflammatory and anti-oxidant properties 
Oxidative stress and Neuro-
inflammation 
Anti-oxidants 
Radical scavengers 
Anti-inflammatory agents 
Transition metal chelators 
Help restore insulin sensitivity and glucose utilization 
Reduce A42 deposition  
Reduce A42 and tau fibrillarization 
Reduce cytokine activation-mediated injury 
Supports microvascular function and cerebral perfusion 
Abbreviations: BACE1=beta site APP cleaving enzyme 1; GLP-1=glucagon-like peptide-1; NMDA= N-methyl-D-aspartate; PPAR= peroxisome proliferator-activated receptor; 
PI3K= phosphoinositol-3- kinase; GSK-3 = glycogen synthase kinase 3; APP= amyloid- - precursor protein; A 42=amyloid beta peptide-42 amino acids 1-42 cleavage product; 
IGF=insulin-like growth factor 
 
tional circumstances, positive responses to treatment with 
intranasal insulin and insulin sensitizer drugs have been ob-
served in subjects with AD [66, 240-246]. However, in order 
to make real progress with respect to treatment, we must 
acknowledge that AD is the end result of a neurodegenera-
tion cascade that progressively targets and cripples different 
aspects of cellular physiology and homeostasis. Therefore, 
one should anticipate that while mono-therapies may be ap-
propriate early in the course of disease, over time, this ap-
proach will be doomed to failure [247]. Such lessons have 
already been learned in the field oncology. Unless we can 
completely prevent AD, multi-pronged approaches will be 
needed to support a range of cellular functions and minimize 
cellular injury and toxicity as the disease progresses. The 
rationale and targets of current and potential future therapies 
for AD are discussed below. 
Cholinergic Deficits and Glutamatergic Dysfunction as 
Targets 
  Acetylcholinesterase inhibitors are used to treat AD be-
cause acetylcholine levels are significantly reduced in the 
early stages of AD [75, 248], and the cholinergic system 
mediates cognitive function and neuronal plasticity. One of 
the major factors contributing to the acetylcholine deficits in 
AD is the loss of cholinergic neurons in the basal forebrain 
[213], as these neurons project widely to the cerebral cortex. 
A second factor is that choline acetyltransferase expression 
and activity are reduced even in viable neurons in brains 
with AD [7, 8]. It is noteworthy that choline acetyltrans-
ferase expression and activity are regulated by insulin/IGF 
stimulation [7, 249]. Although there is no evidence that ace-
tylcholinesterase activity is significantly increased in AD 
brains, the rationale for treating patients with cholinesterase 
inhibitors is that such drugs could help sustain normal levels 
of acetylcholine by reducing the rates of its degradation. In 
addition, cholinesterase inhibitors may have off-target thera-
peutic effects by stimulating production of trophic factors, 
such as growth hormone and IGF-1 [250], which also sup-
port cognitive function. A third reason for administering 
acetylcholinesterase inhibitor drugs is that they may be pro-
tective against glutamate neurotoxicity and promote neuronal 
survival through activation of PI3 kinase-Akt [251]. Cur-
rently, the standard of care for AD includes the use of ace-
tylcholinesterase inhibitors such as donepezil, aricept, 
tacrine, and rivastigmine [252].  
  The more recent addition of glutamate receptor antago-
nists to the AD treatment regimen is based on the concepts 
that L-glutamate functions as an excitatory amino acid neu-
rotransmitter, and that glutamatergic dysfunction in AD 
leads to sustained excitotoxicity with attendant impairment 
of synaptic plasticity needed for learning and memory [253, 
254]. Consequently, antagonists to the N-methyl-D-aspartate 
(NMDA) glutamatergic receptor, such as memantine (Ne-
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tors to support memory in patients with mild to moderate AD 
[255, 256]. Although these approaches provide moderate 
symptomatic relief and delay disease progression in the early 
stages of AD, long-term therapeutic responses are limited at 
best, as these drugs do not arrest or reverse neurodegenera-
tion [257-260]. Therefore, additional approaches are needed, 
and should include drugs that target various components of 
the neurodegeneration cascade. For example, there is evi-
dence suggesting that the combined administration of a ace-
tylcholinesterase inhibitors and anti-oxidants (Formula F or 
Ginkgo biloba-EGb 761) can more effectively improve cog-
nitive performance than either compound alone [261, 262]. 
Since NMDA can promote insulin resistance [263], and 
NMDA neurotoxicity can be attenuated or prevented by in-
sulin stimulation [264]. Therefore, therapeutic measures to 
inhibit glutamate excitotoxicity may help restore brain meta-
bolic functions, particularly in the context of insulin or insu-
lin sensitizer treatments. 
APP-A Accumulation and Production as Therapeutic 
Targets 
  Research is extensively focused on finding safe and ef-
fective means of depleting the brain of toxic APP-A de-
posits, reducing APP-A fibrillarization and aggregation, 
and preventing abnormal cleavage and processing of APP 
[265]. The overarching hypothesis is that APP-A peptides 
are neurotoxic, promote amyloid plaque formation, and me-
diate tau hyper-phosphorylation, fibrillarization, and neu-
rofibrillary tangle formation [266]. Efforts to deplete the 
brain of toxic APP-A led to the development of APP-A-
targeted immunotherapy. Although APP-A active immu-
nization with APP-A peptides, or passive delivery of 
APP-A-specific antibodies can effectively clear APP-A 
plaques from brains of humans and experimental animals 
[267], the net outcomes are not very encouraging because the 
APP-A instead accumulates in vessels, increasing propen-
sity for micro-hemorrhage [268]. Even more disappointing 
were the findings that the effects of APP-A clearance on 
cognitive function have been either modest or undetectable, 
and that patients receiving the vaccine still died with end-
stage dementia and extensive neurofibrillary tangle and neu-
ritic pathology in their brains [269, 270]. Moreover, amyloid 
vaccination produced unacceptable complications such as 
encephalitis mediated by auto-reactive T cell responses and 
vasogenic cerebral edema [267, 270]. 
  Besides the neurological complications of brain swelling, 
particularly in subjects who did not have significant global 
brain atrophy, the root causes of vasogenic edema, i.e. pro-
inflammatory responses with increased microglial activation, 
cerebral amyloid angiopathy, and accumulation of soluble 
neurotoxic oligomeric APP-A [271], may have adversely 
influenced the clinical course of AD. Furthermore, studies 
examining therapeutic effects of passive humanized APP-A 
antibody immunization demonstrated that despite APP-A 
clearance and ample delivery of the antibodies to the brain 
[272], significant therapeutic responses such as improved 
survival or retarded progression from mild or moderate to 
severe dementia could not be demonstrated; consequently, 
those clinical trials were halted [273]. Altogether, the results 
of the APP-A immunization trials suggest that, despite 
promising results in experimental animal models, this ap-
proach alone will not likely succeed for treating AD in hu-
mans. However, before this chapter can be closed, additional 
studies are needed to determine the degree to which pharma-
cological clearance of toxic APP-A or preventing its for-
mation and accumulation in brain can preserve or restore 
cognitive function and slow progression of AD neurodegen-
eration. 
  One potential approach to preventing the formation and 
build-up of toxic APP-A is to inhibit the expression or 
activity of enzymes responsible for aberrant processing and 
cleavage of APP. APP-A is generated by sequential pro-
teolysis, first with beta secretases, then gamma-secretases 
[274]. Presenilins, which are often mutated in early onset 
familial AD, form the catalytic component of gamma-
secretases, which mediate intramembranous cleavage of type 
1 transmembrane proteins, including APP [275]. Mutation 
of presenilin genes leads to accumulation of APP-A in 
AD, as well as other aging-associated neurodegenerative 
diseases, including fronto-temporal lobe and Lewy body 
dementias [275]. To inhibit abnormal processing of APP 
and the attendant accumulation of toxic APP-A, efforts 
have been focused on targeting gamma secretases, including 
for the treatment of sporadic, late-onset AD [276, 277]. Al-
though the pharmacological effects of gamma secretase in-
hibitors proved promising with regard to their ability to ef-
fectively lower plasma, CSF, and brain APP-A burden 
[274, 278], the disappointing result was that objective clini-
cal therapeutic responses to these agents proved to be mini-
mal or undetectable [276, 279, 280]. Worse yet, the com-
pounds proved to be highly toxic due to concurrent inhibition 
of Notch signaling pathways [274, 277]. In the adult brain, 
Notch signaling mediates neuronal plasticity, cognition, and 
long-term memory [281]. 
  To circumvent toxicity-related problems, efforts are un-
derway to develop Notch cleavage-sparing gamma secretase 
inhibitor drugs [282, 283]. Results of clinical trials that may 
be underway are not yet known. However, besides toxicity, 
the potential therapeutic effectiveness of gamma secretase 
inhibitors has been drawn into question because the net ef-
fects of these agents on APP-A levels may be too low to 
improve clinical outcome [277]. The same problem exists 
regarding the use of non-steroidal anti-inflammatory drugs 
(NSAIDs), which have Notch-sparing gamma secretase in-
hibitory effects, but they produce weak clinical therapeutic 
responses [277, 284]. Nonetheless, the potential still exists 
to develop drugs that reduce APP-A burden and toxicity 
by other mechanisms such as, inhibiting beta site APP 
cleaving enzyme 1 (BACE1), increasing expression of alpha 
secretase, or blocking APP-A peptide fibrillization [252].  
  With regard to insulin resistance and the potential contri-
butions of A toxicity, since insulin accelerates trafficking of 
A from the trans-Golgi network to the plasma membrane, 
and extracellular secretion of A [63], and impaired insulin 
signaling disrupts the processing of APP and clearance of 
A [66], it seems likely that by addressing the underlying 
causes of insulin/IGF resistance, we may be able to effec-
tively and safely reduce APP-A burden in the brain. This 
point is reinforced by the finding that IGF-1 and IGF-2 are 
neuroprotective as they reduce the neurotoxic effects of 
APP [70-73]. On the other hand, the fact that APP oli-
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PI3 kinase activation of Akt, which leads to impaired sur-
vival signaling, increased activation of GSK-3, and resul-
tant hyper-phosphorylation of tau, argues in favor of pursu-
ing measures that reduce APP oligomer fibrillarization as a 
means of restoring brain insulin sensitivity.  
Therapeutic Targeting of Tau Hyper-Phosphorylation 
  Hyperphosphorylation of tau leads to misfolding and 
aggregation of oligomeric fibrils, followed by ubiquitination 
and generation of dementia-associate paired helical fila-
ments. Paired-helical filaments form the cores of neurofibril-
lary tangles, neuropil threads, and dystrophic neurites, which 
are structural hallmarks of AD neuropathology. Tau hyper-
phosphorylation is mediated by inappropriate and sustained 
activation of kinases, including GSK-3 [285], cyclin-
dependent kinase -5 (cdk-5), p38 MAPK, and c-jun kinase 
(JNK) [286, 287], and inhibition of phosphatases that medi-
ate physiological dephosphorylation of tau, e.g. protein 
phosphatase-2A [287]. Therefore, treatment with chemical 
inhibitors of one or more of these disease- relevant kinases, 
or phosphatase activators, may reduce the rates of neurofi-
brillary pathology in AD. Among these potential targets, 
somewhat greater attention has been paid to the role of GSK-
3 because, in addition to promoting tau hyper-
phosphorylation, high levels of GSK-3 activity lead to al-
terations in APP processing and increased neuronal death 
[285, 288-290].  
  Approaches to therapeutically inhibiting GSK-3 activity 
have mainly included the use of lithium chloride, and to a 
lesser extent, indigoids [285, 288-291]. Experimentally, lith-
ium chloride treatment of Swedish APP transgenic mice 
reduced GSK-3-induced APP-A accumulation [292, 
293], and treatment of mutant APP and tau double trans-
genic AD mice with the NP12 GSK-3 inhibitor, significantly 
reduced brain amyloid burden, tau alterations, and neuronal 
survival [294]. In contrast, lithium treatment of aged 3xTg-
AD mice reduced tau phosphorylation, but did not alter 
APP-A load or improve performance on working memory 
tasks [295]. Therefore, in several well-characterized experi-
mental models, therapeutic inhibition of GSK-3 prevented 
certain aspects of AD-type neurodegeneration, although the 
results varied, depending on the underlying gene abnormali-
ties.  
  In several uncontrolled or retrospective human clinical 
studies, it was demonstrated that prior use of lithium therapy 
in psychiatric patients was protective against dementia and 
associated with better performance on cognitive tests [296-
299]. In addition, among individuals at risk for early onset 
familial AD, chronic lithium treatment reduced the preva-
lence rates of AD and the brain activity levels of GSK-3, 
and it increased the levels of brain-derived neurotrophic factor 
(BDNF) [300]. However, a subsequent randomized, single-
blind, short-term (10 weeks) placebo-controlled multicenter 
trial proved disappointing in that performance on standard-
ized cognitive function tests was not significantly improved, 
and no significant reductions in CSF GSK-3 activity were 
detected [301]. However, those findings ought to be inter-
preted with caution, given the relatively short duration of the 
trial compared with earlier (uncontrolled) retrospective stud-
ies. 
  Altogether, the effects of GSK-3 inhibitor treatments on 
neurodegeneration and cognitive performance in both human 
and experimental animal studies have been mixed. Variabil-
ity in the diminution of GSK-3-induced pathology, i.e. tau 
phosphorylation, APP-A load, and cognitive function, 
could be attributed to the inadequacy of controls, differences 
in the durations of treatment and observation, nature of the 
underlying mechanisms of neurodegeneration, and variabil-
ity in outcome measurements. Therefore, it may be prema-
ture to abandon this approach without further systematic 
investigation, particularly since the scientific basis for the 
overarching hypothesis is sound. Nonetheless, an important 
caveat with regard to going forward with this therapeutic 
strategy is that efforts should be made to target only the 
GSK-3 activity that is aberrantly increased in the CNS, 
rather than broadly inhibit GSK-3 throughout the brain and 
body. Since GSK-3 is a broadly acting kinase that regulates 
signaling through critical pathways such as Wnt and Notch 
[302, 303], which in the adult CNS are crucial for neural 
stem cell homeostasis [304, 305], chronic global inhibition 
of GSK-3 could have unintended consequences with regard 
to regenerative and repair mechanisms in brain cells that are 
not targeted for neurodegeneration.  
Insulin Therapy  
  The proposed used of anti-diabetes, hypoglycemic drugs 
to treat AD is based on the findings that: 1) AD is associated 
with brain insulin resistance and insulin deficiency (reduced 
brain and CSF levels), with or without associated systemic 
insulin resistance or T2DM; 2) diabetic patients that are 
well-managed with insulin or hypoglycemic medications 
exhibit significant improvements in memory and slowing of 
AD progression; 3) treated elderly diabetics have lower den-
sities of AD lesions compared with non-diabetic controls; 4) 
insulin administration improves cognition and memory in 
AD, and insulin stimulated cognition is correlated with in-
creased levels of norepinephrine in both plasma and CSF 
[306]; 5) hyper-insulinemic euglycemic clamping enhances 
cognition and attention in patients with AD; and 6] experi-
mental intracerebral or intravenous treatments with insulin 
improve memory, cognition, evoked brain potentials, and 
neurotransmitter function [66]. Although attractive and 
seemingly simple, a foremost consideration is the fact that 
the target population consists of elderly individuals who 
probably have other chronic diseases and who are at in-
creased risk for problems related to inadvertent bouts of hy-
poglycemia, e.g. traumatic falls that could be debilitating or 
life-threatening, and metabolic insults to various organs, 
including brain. Moreover, the effectiveness of insulin ther-
apy may be dependent upon simultaneously increased lev-
els/availability of glucose, and it may not be effective in fa-
cilitating memory if CSF APP-A42 levels are markedly 
elevated due to insulin resistance [307]. Therefore, the rou-
tine use of systemic insulin therapy for patients with AD 
would be impractical and probably ill-advised, if not 
unacceptable.  
  However, another approach taken that avoids potentially 
harmful side-effects is to administer intranasal insulin. Intra-
nasal insulin increases brain insulin levels and improves per-
formance on declarative memory tasks while having little 
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tion, intranasal insulin delivered via an electronic atomizer, 
improves attention and increases the APP-A 40/APP-
A42 ratio [245]. Reducing the relative amounts of APP-
A42 should be neuroprotective as APP-A42 is the neuro-
toxic form of the secreted peptide. In a controlled clinical 
trial, ApoE-4-negative individuals were demonstrated to 
benefit significantly from intranasal insulin, as manifested by 
improvements in cognitive performance [308]. The fact that 
ApoE4+ subjects did not benefit from the same treatment 
suggests that intranasal insulin, as well as other pro-
metabolic therapies for AD, may have to be tailored accord-
ing to particular genetic risk factors and biomarkers of dis-
ease.  
INSULIN STIMULATING/RELEASING HORMONES 
(INCRETINS)  
  As an alternative to insulin, another promising approach 
is therapeutic administration of incretins, such as glucagon-
like peptide-1 (GLP-1). GLP-1 is an insulinotropic peptide 
that is generated by cleavage of proglucagon protein, and 
secreted by small intestinal L cells following food intake. 
GLP-1 has a half-life of only a few minutes, and is rapidly 
degraded by dipeptidyl peptidase-4. GLP-1 stimulates insulin 
gene expression and secretion, and suppresses glucagon. 
GLP-1 lowers blood glucose in individuals with T2DM [309, 
310], and it restores insulin sensitivity. The latter attribute is 
perhaps one of the most important considerations for the 
potential use of GLP-1 and related molecules for the treat-
ment of brain insulin resistance in AD.  
  Like insulin, GLP-1 stimulates neuritic growth in CNS 
neurons and exerts neuroprotecive actions against glutamate-
mediated excitotoxity, oxidative stress, trophic factor with-
drawal, and cell death [311-313]. In addition, inhibition of 
dipeptidyl peptidase-4, which degrades GLP-1, reduced oxi-
dative and nitrosative stress, inflammation, memory im-
pairment, and APP-A deposits in an AD transgenic mouse 
model [314]. At the very least, these observations support 
the hypothesis that insulin resistance and deficiency play 
critical roles in the pathogenesis of AD. Importantly, GLP-1 
can cross the blood-brain barrier, and may effectively reduce 
brain APP-A burden in AD [309, 310, 315]. With the re-
alization that GLP-1 has a short half-life and therefore lim-
ited practical use for long-term therapy, synthetic long-
lasting analogues of GLP-1 have been generated and proven 
to be effective in preserving cholinergic neuron function 
[316]. The development of GLP-1 receptor agonists, such as 
Geniposide or Exendin-4, which harbor the same neuro-
protective and neuro-stimulatory properties as GLP-1 [317], 
but have longer half-lives [311, 315, 318, 319], may provide 
effective and standardized long-term options for treating 
brain insulin resistance diseases such as AD. Finally, a future 
approach could be to utilize a form of gene therapy in which 
genetically modified mesenchymal or stem cells are im-
planted into the lateral ventricles for sustained delivery of 
neuro-stimulatory and neuro-protective agonists [320-322], 
including GLP-1 [323]. 
Anti-Hyperglycemic Agents 
  Metformin is a biguanide anti-hyperglycemic drug that is 
used to treat T2DM. Metformin functions by suppressing 
gluconeogenesis and enhancing glucose uptake and insulin 
sensitivity. Metformin treatment is protective against neuro-
logical complications of T2DM, including cognitive impair-
ment and cerebral vascular disease [324]. Although met-
formin treatment was found to increase the generation of both 
intra- and extracellular APP-A due to increased expression 
of BACE1, suggesting that metformin and insulin may have 
opposing effects on APP-A accumulation, the administra-
tion of both insulin and metformin provided significant neu-
roprotection. Importantly, the combined treatments reduced 
APP-A levels, the severity of AD pathology, including 
APP-A neuritic plaques, and oligomeric APP-A-
mediated down-regulation of the insulin receptor. These 
findings suggest that metformin mono-therapy may be harm-
ful due to exacerbation of AD-type neurodegeneration [325], 
whereas the combined use of insulin and hypoglycemic 
drugs may benefit elderly patients in the early stages of AD 
by significantly improving cognitive performance and slow-
ing the rate of neurodegeneration.  
Insulin Sensitizers 
  Peroxisome proliferator-activated receptors [PPAR] are 
steroid hormone super family ligand-inducible transcription 
factors that enhance insulin sensitivity, modulate glucose and 
lipid metabolism, stimulate mitochondrial function, and re-
duce inflammatory responses [326-329]. Three classes of 
PPARs are recognized, PPAR-, PPAR-, and PPAR-. All 
3 are expressed in the adult brain, although PPAR- is most 
abundant, followed by PPAR- [8, 83, 149]. PPAR agonist 
treatments improve cognitive performance in experimental 
animal models [83, 330] and in humans with AD or MCI 
[148, 150, 331]. The PPAR- agonist, rosiglitazone, has been 
most widely studied in human clinical trials. In addition to 
its insulin sensitizing and anti-inflammatory properties, 
rosiglitazone, like metformin, increases expression of the 
GLUT4 glucose transporter and glucose metabolism. 
Moreover, simultaneous treatment with PPAR agonists such 
as, rosiglitazone, enhances the therapeutic effects of met-
formin+insulin.  
  In a small double-blind, placebo-controlled trial, investi-
gators showed that rosiglitazone treatment significantly pre-
served performance on delayed recall and attention tasks 
relative to the placebo-treated group, which continued to 
decline [332]. However, a later study found that rosiglita-
zone therapy was mainly effective in preserving cognition in 
patients who were ApoE 4-negative, while the ApoE 4+ 
subjects showed no improvement or continued to decline 
[333]. Despite promising experimental results, initially posi-
tive clinical studies, and supportive evidence that impaired 
glucose metabolism and insulin resistance are key compo-
nents in the pathogenesis of AD, the most recent outcome of 
a rosiglitazone monotherapy, randomized double-blind pla-
cebo controlled phase III study was negative with respect to 
improvements in objective cognitive assessments, but highly 
statistically significant based on clinical and caregiver im-
pression [334]. Potential explanations for these disappointing 
results include the following: 1) effective treatment of neu-
rodegenerative diseases may require a different isoform of 
PPAR agonist, i.e. PPAR-, since PPAR- is abundantly 
expressed in the brain, and previous studies showed that 
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type neurodegeneration and neurocognitive deficits com-
pared with PPAR- and PPAR- agonists [83]; 2) the biodis-
tribution of the PPAR agonists may not have been optimized 
based on the structure of the compounds; and 3) mono-
therapy may not be sufficient, and instead the combined ad-
ministration of a PPAR agonist with insulin or GLP-1 and 
metformin may be required to effectively treat AD-
associated brain insulin resistance and metabolic dysfunc-
tion. 
Alpha Lipoic Acid (ALA) 
  ALA is a natural compound that supports mitochondrial 
function, serving as a cofactor for pyruvate dehydrogenase 
and alpha ketoglutarate dehydrogenase. Importantly, ALA 
enhances production of acetylcholine by activating choline 
acetyltransferase and increasing glucose uptake [335]. There-
fore, the potential benefits of ALA are mediated by the sup-
portive actions of ALA on insulin and GLP-1. However, 
beyond those effects, ALA has anti-oxidant effects, since it 
serves as an inhibitor of hydroxyl radical formation and can 
scavenge reactive oxygen species and lipid peroxidation 
products such as 4-hydroxy-2-nonenal [335], which are in-
creased in AD brains [336, 337]. In addition, ALA inhibits 
expression of pro-inflammatory cytokines and inflammation-
associated nitric oxide synthase, which have important roles 
in mediating neuro-inflammation in the early stages of AD 
[338-341]. Although there are few clinical trials examining 
the efficacy of ALA therapy for AD, there is some evidence 
that ALA may slow the progression of cognitive impairment 
in patients with moderately severe AD [335].  
Chromium Picolinate  
  Chromium is an often overlooked essential metal that has 
an important role in regulating the actions of insulin, includ-
ing carbohydrate, protein, and lipid metabolism [342-344]. 
Chromium enhances insulin sensitivity by increasing insulin 
receptor binding, insulin receptor number, and insulin inter-
nalization. In addition, chromium lowers blood glucose, 
triglycerides, and low density lipoprotein (LDL) cholesterol, 
increases high density lipoproteins (HDL), and reduces risk 
for cardiovascular disease [345, 346]. Moreover, chromium 
supplementation improves cognitive performance, including 
memory, promotes weight loss, and helps control diabetes. 
Chromium picolinate mediates its effects on body weight by 
reducing food craving and increasing satiety [347]. Although 
food sources of chromium are fairly abundant and include, 
whole grains, lean meats, cheeses, corn oil, black pepper, 
thyme, and brewer’s yeast, most foods contain relatively low 
levels of chromium per serving (1-2 mcg), and most dietary 
forms of chromium are poorly absorbed. On the other hand, 
chromium picolineate, which is highly stable and consists of 
Cr[III] chelated with three molecules of picolinic acid, was 
formulated to increase the bioavailability of ingested chro-
mium [346]. In vivo studies have demonstrated considerable 
safety associated with chromium picolinate use, including 
long-term exposures [348, 349].  
  Although clinical studies investigating the therapeutic 
effects of chromium picolinate supplementation have yielded 
conflicting results, in the vast majority of clinical trials (util-
izing 150-1000 mcg/day), chromium picolinate was found to 
significantly improve glycemic control and reduce blood 
cholesterol and triglyceride levels in diabetics [350]. With 
increasing age, plasma chromium levels decline. This phe-
nomenon could partly account for aging-associated insulin 
resistance and cognitive decline since reduced levels of 
chromium are correlated with cognitive impairment and AD 
[351]. In a recent double-blind placebo controlled clinical 
study, a 12-week period of chromium picolinate supplements 
administered to elderly subjects significantly reduced seman-
tic interference on learning, recall, and recognition memory 
tasks [352]. In addition, functional magnetic resonance imag-
ing demonstrated increased activity in the thalamus, and 
frontal, parietal and temporal lobes of treated subjects, indi-
cating that chromium picolinate can enhance cognitive func-
tion in elderly people [352]. Due to its positive effect on in-
sulin signaling mechanisms and relative safety, it appears 
that chromium supplementation has a role in long-term sup-
port of metabolic pathways, both systemically and within the 
CNS. Given the demonstrated roles of T2DM, obesity, and 
peripheral insulin resistance as mediators of cognitive im-
pairment and neurodegeneration, and supportive evidence 
that improvements in insulin responsiveness enhance cogni-
tive function and reduce neurodegeneration, the inclusion of 
chromium picolinate as a dietary supplement, or develop-
ment of like compounds that achieve the same, or better and 
more reproducible effects could help target fundamental 
metabolic dysfunctions that occur early in the course of AD.  
Antioxidant and Anti-Inflammatory Drugs 
  Antioxidant functions help maintain mitochondrial ho-
meostasis, neuronal activities, and cell survival. Oxidative 
stress plays a pivotal role in the pathogenesis and progres-
sion of AD-type dementia. Sources of oxidative stress in-
clude, impairments in insulin signaling, fibrillarization of 
oligomeric APP-A and tau, mitochondrial dysfunction, 
micro-vascular disease, increased accumulation of ROS, 
RNS and inflammation [353]. Although it has not yet been 
determined which source of oxidative stress in most critical 
to neurodegeneration and cognitive impairment, some doubt 
has been cast upon the role of APP-A since in a longitu-
dinal analysis, significant reductions in plasma APP-A42 
in subjects treated with various anti-inflammatory agents, 
was not associated with improvements in cognition [354]. 
Nonetheless, the interest in reducing oxidative stress in the 
brain is justified as a treatment approach because this type of 
injury could, at the very least, serve as a co-factor mediating 
AD progression. Potential approaches to reduce oxidative 
stress include the use of anti-oxidants, anti-inflammatory 
agents, radical scavengers, transition metal chelators, and 
non-vitamin anti-oxidant polyphenols. 
Vitamin E [Tocopherol]  
  It has anti-oxidant properties, and has been shown to 
modulate signaling and aid in neurotransmitter synthesis. 
However, epidemiological data linking regular use of vita-
min antioxidants to cognitive performance are weak, and 
although prospective longitudinal and interventional studies 
have shown some positive results, the responses detected in 
randomized control studies have been modest [355, 356]. On 
the other hand, discrepancies between clinical trials and epi-
demiological data could be explained by the relatively short 
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practical, versus retrospective analysis of possibly life-long 
exposure effects. The main conclusion that can be drawn 
from the available data is that antioxidant therapy, while 
beneficial, cannot be used as a stand-alone treatment for AD, 
but its use should probably be incorporated into lifestyles.  
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
  Based on epidemiologic studies demonstrating apparently 
reduced risk of developing AD among primarily ApoE4+ 
individuals who had been chronically treated with NSAIDs, 
it was hypothesized that NSAIDs would have efficacy in 
treating AD, or preventing AD development in patients with 
MCI [79, 284, 357-359]. These concepts are supported by 
the fact that neuro-inflammatory responses occur early in the 
course of AD, and they contribute to APP-A deposition 
[360]. In addition, in experimental models, neuro-
inflammation leading to the recruitment and activation of 
microglia and astrocytes, mediates APP-A deposition 
[361]. It was hypothesized that NSAIDs could be used to 
modify AD pathogenesis by suppressing neuro-inflammation 
and slowing APP-A deposition [359, 362, 363]. However, 
in clinical trials, selective cyclooxygenase-2 (COX-2) inhibi-
tor drug therapy proved to be ineffective for treating AD 
[284, 358], and protecting individuals with MCI from pro-
gressing toward AD [284]. These observations make it un-
likely that this avenue of therapy will be useful for modify-
ing the course of AD. 
Radical Scavengers 
  Epidemiological studies suggested that long-term treat-
ment with anti-inflammatory drugs, including NSAIDs, vi-
tamin E, estrogens, and 3-hydroxy-3-methyl-glutaryl-CoA 
(HMG-CoA) reductase inhibitors (statins) might be neuro-
protective in either preventing dementia, or improving clini-
cal outcomes [265]. The potential benefits and limitations of 
NSAIDs and Vitamin E therapy for AD have already been 
discussed. Interest in the role of estrogens was inspired by 
the findings that, estrogens stimulate cognitive performance 
in experimental animals and, bio-available estrogen levels 
decline with advancing age in both sexes [364, 365], Al-
though a few clinical studies showed limited and mainly 
short-term rather than long-term benefits of estrogen therapy 
with respect to cognition [365], better controlled clinical 
trials provided clear evidence that exogenous estrogen ther-
apy does not improves dementia symptoms in women with 
AD, and instead, it increases dementia risk when the treat-
ment is begun after 65 years of age [366, 367]. On the other 
hand, the recent evidence that estrogen receptor modulation 
therapy may improve cognition [364, 368] deserves further 
study.  
  Statins are HMG-CoA reductase inhibitors. HMG-CoA 
catalyzes the rate-limiting step in cholesterol biosynthesis. 
The rationale for using statins to treat AD is that cholesterol 
metabolism and transport are involved in the regulation 
APP-A deposition and tau hyper-phosphorylation [369, 
370]. In addition, cerebrovascular disease, which can cause 
vascular dementia and contribute to AD progression, is asso-
ciated with hypercholesterolemia. Statin therapy has been 
evaluated in clinical trials, and meta analysis of data gener-
ated by large prospective clinical trials revealed no signifi-
cant benefits of atorvastatin or simvastatin therapy in pa-
tients with dementia who had been treated for periods rang-
ing from 26 to 72 weeks, despite significant reductions in 
serum low density lipoprotein (LDL) [371-374]. Still, other 
studies showed significant reductions in incident dementia 
among statin users [375, 376] and experimental data suggests 
that statins may provide some degree of neuroprotection 
[377].  
  In an anti-inflammatory treatment prevention trial, de-
spite a 67% reduction in hazard risk of incident AD among 
individuals treated with lipid-lowering drugs, the most sig-
nificant findings were that HDL was positively correlated 
with mini-mental state examination (MMSE) performance, 
and while LDL cholesterol was negatively correlated with 
immediate and delayed recall [378]. Limitations of this study 
include, its relatively short duration of follow-up and the 
lack of distinction between vascular dementia and AD. How-
ever, the impact of statin therapy was most likely effectuated 
by reduced severity of cerebrovascular disease, lessening its 
contribution to AD progression. Potential concerns over the 
use of statins to treat AD have been raised by the findings 
that: 1] brain cholesterol levels are reduced in AD [370]; 2] 
reductions in neuronal cholesterol lead to impaired insulin 
signaling and energy metabolism [49]; and 3] cognitive im-
pairment can occur with chronic statin use [379-382] and 
following its discontinuation, cognitive function may be re-
stored [380, 382]. These observations suggest that routine 
and preventive use of statin therapy, particularly in the eld-
erly, should be re-evaluated [383] and perhaps avoided un-
less indicated for cardiovascular health. Moreover, future 
studies should assess risk for further cognitive impairment 
among individuals with AD who do not have hyperlipidemia 
or cerebrovascular disease.  
Ginkgo Biloba 
  Ginkgos or Maldenhair Trees, are ancient and have 
served as sources of food and traditional medicine for centu-
ries. Gingko biloba trees are commonly cultivated in China, 
Japan, and North America. Gingko nuts are used in congee, 
and the leaf extracts contain medicinal flavonoids and terpe-
noids. Gingko is thought to have neurotropic properties and 
enhance memory and concentration, suggesting it may be 
useful for treating or preventing AD. Clinical trials designed 
to examine the therapeutic efficacy of gingko biloba have 
mainly used the leaf extract, EGb 761, which contains 24% 
flavone glycosides and 6% terpenoids. Experimentally, EGb 
761 enhances antioxidant capacity of cells by inducing ex-
pression of the glutathione synthesis catalytic subunit, GCLC 
[384]. In humans, EGb761 significantly increases regional 
cerebral blood flow [385], suggesting that its therapeutic 
effects may be mediated by enhanced perfusion. 
  Although short-term effects of Gingko biloba therapy on 
cognitive function have been reported [386], several studies, 
including a community-based pragmatic randomized double-
blind study, detected no significant halting or slowing of 
cognitive decline occurred after a 6-month trial with standard 
Gingko biloba extract [387]. On the other hand, in a 42-
month randomized placebo-controlled, double-blind study, 
after correcting for medication adherence, significant protec-
tive effects of gingko biloba extract (EGb 761), manifested 
by slower rates of cognitive and memory decline, were ob-
served [388]. In another randomized control trial in which 52    Current Alzheimer Research, 2012, Vol. 9, No. 1  Suzanne M. de la Monte 
subjects were administered 240 mg/day of EGb 761 for 22 
weeks, significant improvement in cognitive performance 
was also observed in patients with AD or vascular dementia 
relative to placebo-treated patients [389]. Two independent 
meta analyses analyzing the effectiveness of EGb761 ad-
ministration in 6 months or longer duration clinical trials 
demonstrated statistical trends corresponding to positive or 
protective effects of EGb761 versus placebo, although effect 
sizes were estimated to be moderate [390, 391].  
  Despite discrepancies in study outcomes and conclusions 
due to underpowered designs and short-term follow-up inter-
vals, altogether the data suggest that Ginkgo biloba has mild 
to moderate neuroprotective effects in both AD and vascular 
dementia, and that it may also benefit elderly individuals 
with MCI. The recent meta analyses reports described above 
are encouraging, and support the concept that antioxidants in 
general, and Ginkgo biloba specifically, may be beneficial in 
the therapeutic management of cognitive impairment and 
AD. Importantly, there are no demonstrated safety concerns 
associated with the standard EGb 761 extract dose of 240 
mg/day [392]. The therapeutic mechanisms of action are 
related to improvements in cerebral blood flow and antioxi-
dant properties of the compound.  
Transition Metal Ion Chelators 
  One hypothesis that has remained viable for decades is 
that transition metal ions, including Al (III), Fe (III), Zn (II), 
and Cu (II), cause neurotoxicity and mediate neurodegenera-
tion [393-395], even in the earliest stages of AD [396]. Ex-
cess accumulation of transition metal ions promotes oxida-
tive stress, apoptosis, and aggregation and fibrillarization of 
hyper-phosphorylated tau [397] and APP-A42 [395, 398]. 
Oxidative stress is mediated by the formation of hydroxyl 
radicals following interactions between iron and hydrogen 
peroxide. In AD, brain levels of free heme and hemin are 
significantly elevated [399], and probably contribute to neu-
rodegeneration by inhibiting cholinergic function, altering 
APP-A metabolism, binding to hyper-phosphorylated tau 
and promoting tau aggregation into paired-helical filaments, 
and inducing formation of free radicals [399].  
  Chelation with compounds such as desferrioxamine, 
Feralex-G, or Clioquinol affords neuroprotection by prevent-
ing the aggregation and fibrillarization of APP-A and tau, 
and reducing ROS production [397, 400-402]. Correspond-
ingly, Clioquinol chelation was reported to reduce APP-A 
burden in transgenic mice [400, 401]. Mechanistically, in 
addition to its proposed direct anti-aggregation effects on 
APP-A, chelation therapy could reduce APP-A deposi-
tion by decreasing oxidative stress and ROS [77], which 
could be caused by heme and heavy metals. Chelation ther-
apy for AD has also been tested in humans. In a 2-year long 
randomized placebo-controlled trial of twice daily injections 
of the trivalent chelator, desferrioxamine, the rates of per-
formance decline among patients with probable AD slowed 
significantly [403]. However, in a later uncontrolled clinical 
trial of Clioquinol therapy for AD, the subjects showed only 
modest improvements in clinical ratings [402]. In one case of 
familial AD, clioquinol therapy increased cerebral glucose 
metabolism and stabilized clinical status [404]. Only a few 
studies have linked chelation therapy to improved glucose 
utilization, energy metabolism, and insulin signaling in the 
brain. Nonetheless, the findings that chelation of zinc and 
iron prevents or attenuates streptozocin-, alloxan-, or ferritin-
induced diabetes [405-407], and that desferrioxamine chela-
tion of iron, and dietary restriction of iron increase glucose 
uptake and insulin signaling in hepatocytes [408, 409] are 
intriguing with respect to the roles of brain insulin resistance 
and metabolic dysfunction in the pathogenesis of AD and 
neurodegeneration. Since treatment with antioxidants, Vita-
min E, Vitamin C, Heme oxygenase 1, or metal chelators 
prevents the neurotoxic effects of heme and hemin [410], 
and may also enhance insulin signaling and glucose utiliza-
tion in the brain, heme-induced oxidative stress could poten-
tially be targeted by anti-oxidant and chelation therapy to 
help restore cholinergic function, reduce fibrillarization of tau 
and APP-A42, decrease oxidative stress, and improve 
energy metabolism in the brain. 
  Despite probable benefits, a major limitation of our cur-
rent methods of chelation therapy is that delivery of drugs 
with high Fe (III) binding capacity to the CNS are subopti-
mal [411, 412]. Another point is that caution must be exer-
cised regarding the potential liberal use of chelation therapy 
because iron is needed to generate energy, and copper, man-
ganese, and zinc participate in enzymatic pathways that pro-
tect cells from free radicals and reactive oxygen species, as 
they are functionally required for the activation of superox-
ide dismutases I-III. Therefore, thorough removal of these 
metal ions would be detrimental. To address these problems, 
various compounds have been developed and tested in pre-
clinical models. For example, DP-109 is a lipophilic metal 
chelator that was demonstrated to reduce cerebral APP-A 
burden in Tg2576 transgenic mice [413]. Another approach 
considered was to conjugate chelators to nanoparticles that 
can cross the blood-brain barrier to chelate metal ions, and 
then exit to remove them [414-416]. Recently, Nano-N2PY, 
a prototype nanoparticle-chelator conjugate was demonstrated 
to inhibit APP-A aggregation and reduce APP-A-
associated cortical neuron toxicity in vivo [417]. Another 
novel approach involved the development of site-activated 
multifunctional chelators, such as HLA20A, that become 
activated by binding and inhibiting acetylcholinesterase, 
resulting in the release of an active chelator that reduces 
APP-A fibrillization and oxidative stress [418, 419]. 
Along related lines, dual target-directed 1,3-diphenylurea 
derivatives seem capable of both inhibiting BACE1 and 
chelating metal ions [420]. 
Polyphenols [Red Wine, Green Tea, and Curcumin] 
  Epidemiological studies demonstrated relative protection 
from dementia, AD, and Parkinson's disease among indi-
viduals who regularly consumed green tea or red wine [421]. 
Resveratrol, 3.4',5-trihydroxy-trans-stilbene, is a natural 
polyphenol that is abundantly present in red wine and has 
antioxidant and neuroprotective activities. Besides red wine, 
other substances such as grape seed extracts, contain resveri-
trol and therefore also provide neuroprotection [422, 423]. 
Pharmacokinetic studies have affirmed that grape seed poly-
phenols abundantly distribute to the brain [424]. Experimen-
tally, resveratrol's neuroprotective effects are mediated by 
enhancement of glutathione free radical scavenger activity 
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increased clearance via the proteasome [428] or autophagy 
and lysosomal degradation [429]. Resveratrol also exerts 
cytoprotective effects by stimulating heme oxygenase, and 
modulating cellular resistance to insults such as compro-
mised blood flow, injury, and inflammation [430]. In addi-
tion, resveratrol and other polyphenols are effective metal 
chelators, and protect the brain from oxidative stress and 
ROS generation caused by accumulations of lead, iron, alu-
minum, zinc, and copper [431]. 
  One very interesting effect of resveratrol is its ability to 
retard aging and protect against AD due to stimulation of the 
sirtuin protein, SIRT1 [432]. Sirtuin genes promote longev-
ity, and SIRT1-mediated deacetylase activity protects against 
AD-type neurodegeneration [433, 434]. Mechanistically, 
SIRT1 functions by interfering with APP-A peptide gen-
eration [433, 434], and SIRT1-activating molecules such as 
resveratrol, were shown to reduce neurodegeneration and 
prevent learning impairments in the p25 transgemic mouse 
model of AD, which is associated with tau hyper-
phosphorylation and fibrillarization [435]. Importantly, 
SIRT1 activation achieves the same effect as caloric restric-
tion with respect to preventing aging and AD [436]. Caloric 
restriction with weigh loss is a well-established means of 
increasing insulin sensitivity, and it works by activating the 
forkhead transcription factor, FoxO3a, which is a key regula-
tor of insulin and IGF-1 signaling [437]. In AD brains, 
FoxO3a activity is reduced [437], corresponding with the 
impairments in insulin and IGF-1 signaling.  
  The major green tea polyphenolic compound, epigallo-
catechin-3-gallate (EGCG), has neuroprotective actions simi-
lar to those of resveritrol. Studies have shown that EGCG: 1) 
mimics cellular effects of insulin, reducing gluconeogenesis 
and corresponding enzyme gene expression [438]; 2) reduces 
APP-A levels by enhancing cleavage and clearance of the 
C-terminal fragment of APP [439]; 3) functions as an iron 
chelating and mitochondrial stabilization compound [440, 
441]. Moreover, clinical trials have demonstrated that EGCG 
has neuroprotective and anti-oxidant therapeutic effects in 
AD, as well as Parkinson's disease [439, 441]. To circumvent 
problems related to dosing and CNS delivery, nanolipidica 
EGCG particles have been generated and already shown to 
improve brain distribution following oral administration 
[442].  
  Curcumin [tetrahydrocurmin], a yellow polyphenol and 
the active component in tumeric, functions as an anti-
diabetic, anti-oxidant, anti-lipidemic, anti-inflammatory 
compound [443-448], similar to the effects of resveratrol and 
EGCG. Curumin induces glucose uptake through phosphory-
lation of AMP kinase (AMP-activated protein kinase /acetyl-
CoA carboxylase) and GLUT4 translocation to the cell sur-
face. Curcumin also enhances insulin sensitivity, resulting in 
synergistic activation of the AMPK and PI3K/Akt pathways 
[449]. In addition, curcumin increases pancreatic islet cell 
insulin secretion, possibly through increased expression of 
heme-oxygenase 1 [450]. Even in established cases of diabe-
tes mellitus, curcumin has demonstrated hypoglycemic ef-
fects via reversal of gluconeogenic enzymes, reducing levels 
of glycosylated hemoglobin (HbA(1C)), and increasing 
plasma insulin, glycogen, and C-peptide [451, 452]. Recent 
studies showed that curcumin significantly increases expres-
sion of GLUT3, acetylcholine receptors, and insulin recep-
tors [453], and decreases lipid peroxidation [454] in brains of 
experimental animals with streptozocin-induced diabetes, 
and neurodegeneration. Together, the data point favorably 
toward the neuroprotective, anti-aging, and anti-oxidant ef-
fects of polyphenols. In addition, the findings demonstrate 
that polyphenols mediate their effects by enhancing insulin 
and IGF signaling, and quite likely stimulate sirtuin signal-
ing, which accomplishes all of the aforementioned therapeu-
tic effects of polyphenols. In addition, the aggregate results 
give strong support to the concept that impaired brain insu-
lin/IGF signaling and energy metabolism play pivotal roles 
in the pathogenesis of AD. This leads to the obvious conclu-
sion that, in addition to multi-modal pharmaceutical target-
ing of brain insulin/IGF resistance, oxidative stress, inflam-
mation [metal ion accumulation], and APP-A and tau 
misfolding and fibrillarization, lifestyle measures could be 
effective in helping to prevent or delay the onset of aging-
associated neurodegenerative diseases, including AD.  
Diet, Supplements, and Lifestyle 
  There is little doubt that the explosion in insulin resis-
tance diseases, including diabetes, obesity, non-alcoholic 
fatty liver disease, polycystic ovarian disease, and dementia, 
followed revolutionary changes in the Western diet that re-
sulted in an exponential rise in the consumption of highly 
processed foods that either lack the appropriate nutrients for 
long-term support of CNS and systemic metabolic functions, 
or contain added ingredients that impair protective actions of 
natural food substances [455]. Until recently, long-term pro-
active nutritional support has taken a back seat with respect 
to disease prevention, particularly among allopathic physi-
cians. In retrospect, the concept is illogical given the clear 
evidence that: 1) certain amino acids help elaborate neuro-
transmitters and trophic factors for brain function; 2) omega-
3, other essential fatty acids, and Vitamin E (alpha toco-
pherol) [456] support membrane maintenance and renewal 
needed for neuronal plasticity; 3) Vitamins A, C, E, and beta 
carotene have anti-oxidant properties; and 4) many B vita-
mins, including Vitamins B1 (thiamine), B2 (riboflavin), B3 
(niacin), B6 (pyridoxine), B9 (folate), and B12 (cobalamin) 
are required for a broad range of neurological functions, in-
cluding cognition [457].  
  Omega-3-fatty acids function as ROS scavengers, and 
they are essential for brain growth and function throughout 
life. For example omega-3 fatty acids modulate various neu-
ronal functions, protect against neuronal oxidative stress, and 
inhibit signaling pathways that promote tau phosphorylation 
and assembly into paired helical filaments [458]. Aging-
associated cognitive impairments have been linked to 
omega-3-fatty acid deficiencies, while dietary supplementa-
tion with docosahexaenoic acid (DHA), which is the major 
form of omega-3 fatty acid found in neurons and available in 
the diet from oily fish [459], was shown to be neuroprotec-
tive in lowering the risks of cognitive impairment and AD 
[458, 459]. Observational studies provide positive evidence 
that chronic omega-3 ingestion is beneficial to cognitive 
function [458, 460, 461], while low fish consumption in-
creases risk for AD [462]. Experimentally, eicosapentaenoic 
acid (EPA) and DHA reduce APP-A fragment formation, 
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servational and epidemiological studies positively support 
the concept that omega-3 and other essential fatty acids 
should be regularly incorporated into the diet, specific guide-
lines regarding dosages and frequency are difficult to estab-
lish because firm conclusions can seldom be drawn based on 
short-term clinical trials [460] 
  With regard to the B vitamins, thiamine (B1) is needed 
for glucose metabolism and energy production, and thiamine 
deficiency syndromes include psychosis, dementia, periph-
eral neuropathy, and heart failure. Folate (B9) preserves 
memory during aging, and when combined with vitamin 
B12, delays the onset of dementia. Deficiencies in pyradox-
ine [B6] and cobalamin [B12] are correlated with cognitive 
impairment. In addition, B12 negatively regulates plasma 
homocysteine, and high levels of homocysteine increase risk 
for cardiovascular disease, cerebrovascular disease, and cog-
nitive impairment. In short, deficiencies in B vitamins lead to 
chronic disablement of insulin signal transduction pathways, 
neurotransmitter functions, and cognition. Although many 
studies designed to objectively examine the therapeutic ef-
fectiveness of vitamin and nutritional supplements for 
preventing neurodegeneration have failed, conclusions 
drawn from their negative results should be cautious because 
for the most part, the study designs tend to be either 
underpowered or too limited in duration to achieve 
statistically significant results [464]. Conceivably, 
population based epidemiologic studies, combined with 
experimentation, may provide the best guidance for the long-
term use of dietary supplements for brain health. 
  Based on data culled from a broad range of studies on the 
effectiveness of lifestyle and dietary measures for supporting 
brain health and providing some degree of neuroprotection, 
the following conclusions could be drawn: 1) aerobic exer-
cise and caloric restriction significantly improve cognitive 
performance and slow progression toward neurodegenera-
tion. These effects are mediated by enhancement of insulin 
and IGF responsiveness and slowing of the aging process, in 
part due to SIRT1 activation. Aging is by far the most sig-
nificant risk factor for AD [434, 436, 465-470] and AD is 
mediated in large measure by brain insulin resistance and 
impaired energy metabolism [7, 8]. Therefore, measures that 
support or bolster insulin sensitivity, including exercise, ca-
loric restriction, and loss of excess weight retard both aging 
and lower the risk of AD; 2) dietary supplements such as 
omega-3 fatty acids and compounds such as chromium pi-
colinate, curcumin, alpha lipoic acid, cinnamon, and red 
bean lectin (stimulates GLP-1), that have insulin sensitizing 
properties [471], could help support neuronal plasticity and 
signaling mechanisms that regulate neuronal metabolism and 
reduce fibrillarization of APP-A and tau [394]; 3) agents 
that reduce oxidative stress, including fat soluble vitamins, 
natural statins such as those supplied in red yeast rice, and 
polyphenols, including those present in red wine, green tea, 
curcumin, and soy isolate protein [472], reduce the genera-
tion of reactive oxygen and reactive nitrogen species, DNA 
damage, and activation of pro-inflammatory, pro-injury, and 
pro-death signaling; 4) ample supplementation with multiple 
B vitamins that support nervous system and cardiovascular 
function, and reduce homocysteine levels [473] are neuro-
protective.  
  In summary, a vast volume of literature has been summa-
rized and discussed in an attempt to demonstrate how seem-
ingly disparate concepts and opinions about the mechanisms 
of neurodegeneration actually converge toward a relatively 
recently appreciated theme that impairments in brain insulin 
and IGF signaling and responsiveness are at the core of AD. 
Insulin and IGF resistance can account for the deficits in 
brain glucose utilization and energy metabolism that are de-
tectable early in the course of AD. The attendant inhibition 
of insulin/IGF signaling leads to aberrant activation of 
kinases that lead to tau hyper-phosphorylation. Impairments 
in energy metabolism and glucose utilization have broad 
consequences due to increased oxidative stress, activation of 
pro-inflammatory cascades, and ROS generation, all of 
which promote aberrant APP expression and cleavage, 
APP-A42 accumulation, and fibrillarization and misfold-
ing of tau and APP-A. Increased ROS production causes 
electrophilic attacks on proteins, lipids, and nucleic acids, 
resulting in the formation of adducts that promote further 
structural and functional damage, oxidative stress, ubiquiti-
nation of proteins, targeting them for degradation. Insu-
lin/IGF resistance impairs lipid metabolism, leading to dis-
ruption of myelin homeostasis. AD is associated with white 
matter atrophy, myelin loss, and increased myelin break-
down with production of potentially toxic sphingolipids, 
including ceramides. Neurotoxic ceramides promote insulin 
resistance, neuroinflammation, and oxidative stress. Finally, 
brain insulin/IGF resistance can also explain the frequent co-
existence of cerebral microvascular disease, which substan-
tially contributes to the neuropathology of AD.  
  Genetic or familial forms of AD represent the minority of 
the overall population at risk for developing AD. Although 
valuable lessons have been and will continue to be learned 
by studying genetic forms of this disease, future efforts 
should be focused on understanding factors that contribute to 
the pathogenesis and progression of sporadic AD. Certainly 
the extremely rapid rise in AD prevalence rates, manifested 
by up to several hundred-fold higher age-adjusted rates in 
2005 compared with 1980 cannot be explained by genetic 
factors, and instead parallels trends that characterize expo-
sure models of disease [1]. In fact, the age-adjusted trends in 
AD prevalence rates are similar to those observed for diabe-
tes mellitus [1]. Although we do not know the cause[s] of 
AD, epidemiological, observational, and experimental evi-
dence together support the hypothesis that AD is a metabolic 
disease with virtually all of the features of diabetes mellitus, 
but largely confined to the brain. One very important conclu-
sion that could be drawn from this review is that the concept 
of using mono-therapy to treat AD is wrong, and instead, 
multiple targets must be attacked simultaneously and over a 
prolonged period of time [260, 474], similar to current ap-
proaches used to treat malignancies. Future multi-modal 
therapies for AD should be directed at multiple levels of 
demonstrated weakness within the insulin/IGF signaling cas-
cade, beginning with receptor sensitizers, agents to promote 
insulin production and release, e.g. GLP-1, inhibitors of oxi-
dative stress, radical formation, and metal ion accumulation, 
tau phosphorylating kinase modulators, and co-factors that 
support glucose utilization, mitochondrial function, and en-
ergy metabolism. If effective, these combined treatments will 
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neuronal plasticity, and neuronal survival, which are needed 
to preserve cognitive function. 
  Complementary and alternative medicine approaches 
have been used extensively and for centuries throughout the 
world. The institution of modern medicine has concerns and 
reservations about embracing the philosophies of naturo-
pathic, homeopathic, and complementary and alternative 
medicine because allopathic medicine is evidence-based, i.e. 
based on objective scientific and clinical experimentation. 
As modern medicine advances scientifically, personalized 
diagnostics and therapeutics will continue to grow more 
mechanized, molecular, biochemical, and genetic test-driven, 
and algorithm-based. However, the unintended consequences 
include, rank dismissal or abandonment of common-sense 
preventive and counseling approaches. Unfortunately, we are 
still without effective means to accurately detect and charac-
terize AD in its early stages, when it would be most respon-
sive to treatment, and we lack effective and universally ac-
cepted long-term approaches to treatment and prevention of 
AD, despite enormous effort and funds spent over the past 
several decades. Inconsistencies among studies designed to 
evaluate the effectiveness of natural compounds for treating 
or preventing neurodegeneration stem from observational 
versus double-blind placebo controlled clinical trials, with 
generally more favorable data obtained from the former 
[475]. 
  Frustration over the lack of answers and sustained posi-
tive outcomes from state-of-the-art therapy, has probably 
helped to fuel the growing utilization of complementary and 
alternative medicine to treat AD. Instead of focusing on the 
use of pharmaceutical grade, FDA-approved drugs, emphasis 
is placed on lifestyle modifications, diet, macronutrient and 
micronutrient supplements, and consumption of natural 
compounds to prevent, retard, or cure chronic diseases [476]. 
These approaches are generally dismissed outright, or met 
with heavy skepticism due to the lack of clear and systematic 
guidelines for evaluating effectiveness of complementary 
and alternative therapies for improving cognitive perform-
ance [477]. Moreover, although specific nutritional deficien-
cies have been correlated with particular disease states, 
growth in our knowledge of how micro- and macronutrients 
contribute to brain and bodily health, and how they may pre-
vent, delay, or modify the course of chronic disease, has 
been slow. Finally, many studies designed to objectively 
examine the effectiveness of these alternative approaches 
have been either underpowered or too limited in duration to 
achieve statistically significant results, leading some to con-
clude that such measures would be fruitless [464]. Conceiva-
bly, population based epidemiologic studies, combined with 
experimentation, may provide the best guidance in the long-
term use of dietary supplements.  
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